UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________
FORM 10-Q
___________________________________________
(Mark One)
|
| |
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the quarterly period ended September 30, 2017March 31, 2018 |
OR
|
| |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the transition period from to . |
Commission File Number 001-33124
___________________________________________
INNOPHOS HOLDINGS, INC.
(Exact Name of Registrant as Specified in its Charter)
___________________________________________
|
| | |
Delaware | | 20-1380758 |
(State or Other Jurisdiction of Incorporation or Organization) | | (I.R.S. Employer Identification No.) |
| |
259 Prospect Plains Road Cranbury, New Jersey | | 08512 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (609) 495-2495
____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” "accelerated filer," “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
| | | | |
Large Accelerated Filer | x | | Accelerated Filer | o |
Non-accelerated filer | o | | (Do not check if a smaller reporting company) | |
| | | Smaller reporting company | o |
| | | Emerging growth company | o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of October 26, 2017,May 7, 2018, the registrant had 19,528,99219,540,584 shares of common stock outstanding.
TABLE OF CONTENTS
|
| | |
| | Page |
| Financial Information | |
| | |
Item 1. | | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
| | |
| Other Information | |
| | |
Item 1. | | |
Item 1A. | | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
Item 5. | | |
Item 6. | | |
| | |
| | |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Unless the context requires otherwise, references to “Innophos,” “the Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q refer to Innophos Holdings, Inc. and its consolidated subsidiaries.
This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and/or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.
The forward-looking statements in this Quarterly Report on Form 10-Q may include, among other things, statements aboutabout: (1) global macroeconomic conditions and trends; (2) the behavior of financial markets, including fluctuations in foreign currencies, interest rates and turmoil in capital markets; (3) changes in regulatory controls regarding tariffs, duties, taxes and income tax rates; (4) our plans, objectives, goals, strategies, future events, future revenues orability to implement and refine our Vision 2022 growth plan; (5) our ability to successfully identify and complete acquisitions in line with our Vision 2022 growth plan and effectively operate and integrate acquired businesses to realize the anticipated benefits of those acquisitions; (6) our ability to realize expected cost savings and efficiencies from our performance capital expenditures, financing needs, plans or intentions relatingimprovement and other optimization initiatives; (7) our ability to acquisitions, theeffectively compete in our markets, and to successfully develop new and competitive products that appeal to our customers; (8) changes in consumer preferences and demand for our products or a decline in consumer confidence and services,spending; (9) our ability to benefit from our investments in assets and human capital and the marketsability to complete projects successfully and on budget; (10) economic, regulatory and political risks associated with our international operations, most notably Mexico and China; (11) volatility and increases in the price of raw materials, energy and transportation, and fluctuations in the quality and availability of raw materials and process aids; (12) the impact of a disruption in our supply chain or our relationship with our suppliers; (13) our ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws; (14) our ability to meet quality and regulatory standards in the various jurisdictions in which we competehave operations or conduct business; and (15) other information that is not historical informationinformation.
You should refer to “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2016,2017, filed with the Securities and Exchange Commission on February 28, 2017,March 1, 2018, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations.
Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
You should read this Quarterly Report on Form 10-Q and any documents that we reference in this report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
PART I - FINANCIAL INFORMATION
| |
ITEM 1. | FINANCIAL STATEMENTS |
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)
| | | September 30, 2017 | | December 31, 2016 | March 31, 2018 | | December 31, 2017 |
ASSETS | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents | $ | 32,732 |
| | $ | 53,487 |
| $ | 40,722 |
| | $ | 28,782 |
|
Accounts receivable, net of allowance for doubtful accounts ($483 and $164) | 102,162 |
| | 77,692 |
| |
Accounts receivable, net of allowance for doubtful accounts ($751 and $445) | | 106,675 |
| | 100,820 |
|
Inventories | 148,536 |
| | 128,295 |
| 154,474 |
| | 145,685 |
|
Other current assets | 25,479 |
| | 23,894 |
| 24,672 |
| | 24,969 |
|
Total current assets | 308,909 |
| | 283,368 |
| 326,543 |
| | 300,256 |
|
Property, plant and equipment, net | 211,601 |
| | 205,459 |
| 220,567 |
| | 219,297 |
|
Goodwill | 139,459 |
| | 84,373 |
| 152,700 |
| | 152,700 |
|
Intangibles and other assets, net | 110,797 |
| | 69,811 |
| 109,945 |
| | 112,916 |
|
Total assets | $ | 770,766 |
| | $ | 643,011 |
| $ | 809,755 |
| | $ | 785,169 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | |
Current liabilities: | | | | | | |
Current portion of capital leases | $ | 4 |
| | $ | — |
| $ | 4 |
| | $ | 4 |
|
Accounts payable, trade and other | 59,969 |
| | 51,611 |
| 63,975 |
| | 70,445 |
|
Other current liabilities | 47,945 |
| | 43,605 |
| 37,300 |
| | 43,084 |
|
Total current liabilities | 107,918 |
| | 95,216 |
| 101,279 |
| | 113,533 |
|
Long-term debt and capital leases | 295,006 |
| | 185,000 |
| 345,004 |
| | 310,005 |
|
Other long-term liabilities | 14,072 |
| | 15,569 |
| 27,259 |
| | 28,072 |
|
Total liabilities | $ | 416,996 |
| | $ | 295,785 |
| $ | 473,542 |
| | $ | 451,610 |
|
Commitments and contingencies (note 14) |
|
| |
|
| |
Common stock, par value $.001 per share; authorized 100,000,000; issued 22,863,478 and 22,777,690; outstanding 19,528,932 and 19,455,011 shares | 20 |
| | 19 |
| |
Commitments and contingencies (note 15) | |
|
| |
|
|
Common stock, par value $.001 per share; authorized 100,000,000; issued 22,889,601 and 22,884,588; outstanding 19,536,038 and 19,537,872 shares | | 20 |
| | 20 |
|
Paid-in capital | 136,598 |
| | 134,694 |
| 138,561 |
| | 137,617 |
|
Common stock held in treasury, at cost (3,334,546 and 3,322,679 shares) | (175,789 | ) | | (175,051 | ) | |
Common stock held in treasury, at cost (3,353,563 and 3,346,716 shares) | | (176,497 | ) | | (176,246 | ) |
Retained earnings | 394,645 |
| | 389,048 |
| 375,938 |
| | 374,366 |
|
Accumulated other comprehensive loss | (1,704 | ) | | (1,484 | ) | (1,809 | ) | | (2,198 | ) |
Total stockholders' equity | 353,770 |
| | 347,226 |
| 336,213 |
| | 333,559 |
|
Total liabilities and stockholders' equity | $ | 770,766 |
| | $ | 643,011 |
| $ | 809,755 |
| | $ | 785,169 |
|
See notes to condensed consolidated financial statements
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Income (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)
| | | Three months ended | | Nine months ended | Three months ended |
| September 30, 2017 | | September 30, 2016 | | September 30, 2017 | | September 30, 2016 | March 31, 2018 | | March 31, 2017 |
Net sales | $ | 183,839 |
| | $ | 186,037 |
| | $ | 528,923 |
| | $ | 557,555 |
| $ | 205,440 |
| | $ | 165,944 |
|
Cost of goods sold | 142,870 |
| | 145,497 |
| | 412,335 |
| | 440,149 |
| 163,213 |
| | 129,401 |
|
Gross profit | 40,969 |
| | 40,540 |
| | 116,588 |
| | 117,406 |
| 42,227 |
| | 36,543 |
|
Operating expenses: | | | | | | | | | | |
Selling, general and administrative | 20,894 |
| | 17,749 |
| | 60,069 |
| | 51,716 |
| 22,520 |
| | 19,322 |
|
Research & development expenses | 1,065 |
| | 896 |
| | 2,713 |
| | 2,913 |
| 1,411 |
| | 830 |
|
Total operating expenses | 21,959 |
| | 18,645 |
| | 62,782 |
| | 54,629 |
| 23,931 |
| | 20,152 |
|
Operating income | 19,010 |
| | 21,895 |
| | 53,806 |
| | 62,777 |
| 18,296 |
| | 16,391 |
|
Interest expense, net | 1,630 |
| | 1,915 |
| | 4,435 |
| | 5,627 |
| 2,904 |
| | 1,353 |
|
Foreign exchange loss (gain) | 100 |
| | 110 |
| | (35 | ) | | 426 |
| (196 | ) | | (57 | ) |
Other income (loss), net | | (15 | ) | | (14 | ) |
Income before income taxes | 17,280 |
| | 19,870 |
| | 49,406 |
| | 56,724 |
| 15,603 |
| | 15,109 |
|
Provision for income taxes | 5,698 |
| | 6,227 |
| | 15,678 |
| | 18,135 |
| 4,688 |
| | 4,186 |
|
Net income | $ | 11,582 |
| | $ | 13,643 |
| | $ | 33,728 |
| | $ | 38,589 |
| $ | 10,915 |
| | $ | 10,923 |
|
Net income attributable to participating common shareholders | $ | 11,513 |
| | $ | 13,548 |
| | $ | 33,540 |
| | $ | 38,356 |
| $ | 10,893 |
| | $ | 10,873 |
|
Per share data (note 3): | | | | | | | | | | |
Income per participating share: | | | | | | | | | | |
Basic | $ | 0.59 |
| | $ | 0.70 |
| | $ | 1.73 |
| | $ | 1.99 |
| $ | 0.56 |
| | $ | 0.56 |
|
Diluted | $ | 0.58 |
| | $ | 0.69 |
| | $ | 1.70 |
| | $ | 1.96 |
| $ | 0.55 |
| | $ | 0.55 |
|
Weighted average participating shares outstanding: | | | | | | | | | | |
Basic | 19,412,474 |
| | 19,294,070 |
| | 19,395,317 |
| | 19,255,143 |
| 19,501,346 |
| | 19,376,258 |
|
Diluted | 19,699,052 |
| | 19,670,159 |
| | 19,695,530 |
| | 19,572,003 |
| 19,711,112 |
| | 19,694,751 |
|
| | | | | | | | | | |
Other comprehensive (loss) income, net of tax: | | | | | | | | |
Change in interest rate swaps, (net of tax of $31, ($126), ($22), and $143) | $ | (52 | ) | | $ | 204 |
| | $ | 35 |
| | $ | (234 | ) | |
Change in pension and post-retirement plans, (net of tax of $43, ($24), $111, and $10) | (103 | ) | | 78 |
| | (255 | ) | | (12 | ) | |
Other comprehensive loss, net of tax | $ | (155 | ) | | $ | 282 |
| | $ | (220 | ) | | $ | (246 | ) | |
Other comprehensive income (loss), net of tax: | | | | |
Change in interest rate swaps, (net of tax of $0 and ($56)) | | $ | — |
| | $ | 92 |
|
Change in pension and post-retirement plans, (net of tax of $243 and ($10)) | | 389 |
| | (5 | ) |
Other comprehensive income (loss), net of tax | | $ | 389 |
| | $ | 87 |
|
Comprehensive income | $ | 11,427 |
| | $ | 13,925 |
| | $ | 33,508 |
| | $ | 38,343 |
| $ | 11,304 |
| | $ | 11,010 |
|
See notes to condensed consolidated financial statements
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in thousands)
| | | Nine months ended | Three months ended |
| September 30, 2017 | | September 30, 2016 | March 31, 2018 | | March 31, 2017 |
Cash flows provided from operating activities | | | | |
Cash flows used for operating activities | | | | |
Net income | $ | 33,728 |
| | $ | 38,589 |
| $ | 10,915 |
| | $ | 10,923 |
|
Adjustments to reconcile net income to net cash provided from operating activities: | | | | |
Adjustments to reconcile net income to net cash used for operating activities: | | | | |
Depreciation and amortization | 29,009 |
| | 28,607 |
| 11,364 |
| | 9,581 |
|
Amortization of deferred financing charges | 322 |
| | 505 |
| 108 |
| | 107 |
|
Deferred income tax (benefit) provision | (14 | ) | | 363 |
| |
Gain on sale of building | (153 | ) | | — |
| — |
| | (153 | ) |
Share-based compensation | 2,996 |
| | 2,329 |
| 998 |
| | 717 |
|
Changes in assets and liabilities: | | | | | | |
Increase in accounts receivable | (13,024 | ) | | (107 | ) | (5,841 | ) | | (6,748 | ) |
Decrease in inventories | 2,873 |
| | 33,092 |
| |
Decrease in other current assets | 151 |
| | 2,102 |
| |
Increase in inventories | | (8,772 | ) | | (9,228 | ) |
Decrease (increase) in other current assets | | 308 |
| | (4,194 | ) |
Decrease in accounts payable | (7,566 | ) | | (2,545 | ) | (6,581 | ) | | (5,973 | ) |
Increase (decrease) in other current liabilities | 1,666 |
| | (16,145 | ) | |
Decrease in other current liabilities | | (5,856 | ) | | (3,827 | ) |
Changes in other long-term assets and liabilities | (3,331 | ) | | (4,986 | ) | (837 | ) | | (1,884 | ) |
Net cash provided from operating activities | 46,657 |
| | 81,804 |
| |
Net cash used for operating activities | | (4,194 | ) | | (10,679 | ) |
Cash flows used for investing activities: | | | | | | |
Capital expenditures | (24,650 | ) | | (25,675 | ) | (9,399 | ) | | (8,553 | ) |
Proceeds from sale of building | 1,028 |
| | — |
| — |
| | 1,028 |
|
Acquisition of Novel Ingredients, net of cash acquired | (124,984 | ) | | — |
| |
Net cash used for investing activities | (148,606 | ) | | (25,675 | ) | (9,399 | ) | | (7,525 | ) |
Cash flows provided by (used for) financing activities: | | | | | | |
Proceeds from exercise of stock options | — |
| | 9 |
| |
Long-term debt borrowings | 146,000 |
| | 36,000 |
| 40,000 |
| | 14,000 |
|
Long-term debt repayments | (36,000 | ) | | (49,002 | ) | (5,000 | ) | | (10,000 | ) |
Excess tax deficiency from exercise of stock options | — |
| | (346 | ) | |
Restricted stock forfeitures | (738 | ) | | (331 | ) | (251 | ) | | (360 | ) |
Dividends paid | (28,095 | ) | | (27,891 | ) | (9,380 | ) | | (9,349 | ) |
Net cash provided by (used for) financing activities | 81,167 |
| | (41,561 | ) | 25,369 |
| | (5,709 | ) |
Effect of foreign exchange rate changes on cash and cash equivalents | 27 |
| | 323 |
| 164 |
| | 226 |
|
Net change in cash | (20,755 | ) | | 14,891 |
| 11,940 |
| | (23,687 | ) |
Cash and cash equivalents at beginning of period | 53,487 |
| | 17,905 |
| 28,782 |
| | 53,487 |
|
Cash and cash equivalents at end of period | $ | 32,732 |
| | $ | 32,796 |
| $ | 40,722 |
| | $ | 29,800 |
|
See notes to condensed consolidated financial statements
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Statement of Stockholders’ Equity (Unaudited)
(Dollars and shares in thousands)
| | | Number of Common Shares | | Common Stock | | Retained Earnings (Deficit) | | Paid-in Capital / Treasury Stock | | Accumulated Other Comprehensive Income/(Loss) | | Total Shareholders' Equity | Number of Common Shares | | Common Stock | | Retained Earnings (Deficit) | | Paid-in Capital / Treasury Stock | | Accumulated Other Comprehensive Income/(Loss) | | Total Shareholders' Equity |
Balance, December 31, 2015 | 19,290 |
| | $ | 19 |
| | $ | 378,321 |
| | $ | (42,286 | ) | | $ | (2,794 | ) | | $ | 333,260 |
| |
Balance, December 31, 2016 | | 19,455 |
| | $ | 19 |
| | $ | 389,048 |
| | $ | (40,357 | ) | | $ | (1,484 | ) | | $ | 347,226 |
|
Net income | | | | | 47,971 |
| | | | | | 47,971 |
| | | | | 22,445 |
| | | | | | 22,445 |
|
Other comprehensive income, (net of tax $(725)) | | | | | | | | | 1,310 |
| | 1,310 |
| |
Other comprehensive income, (net of tax $241) (a) | | | | | | | | | | (714 | ) | | (714 | ) |
Effects of U.S. enacted Tax Cuts and Jobs Act (a) | | | | | | 293 |
| | | | | | 293 |
|
Proceeds from stock award exercises and issuances | 192 |
| | | | | | (1,428 | ) | | | | (1,428 | ) | 108 |
| | 1 |
| | | | (900 | ) | | | | (899 | ) |
Share-based compensation | | | | | | | 3,732 |
| | | | 3,732 |
| | | | | | | 3,823 |
| | | | 3,823 |
|
Excess tax deficiency from exercise of stock options | | | | | | | (9 | ) | | | | (9 | ) | | | | | | |
|
| | | | — |
|
Restricted stock forfeitures | (27 | ) | | | | | | (366 | ) | | | | (366 | ) | (25 | ) | | | | | | (1,195 | ) | | | | (1,195 | ) |
Dividends declared | | | | | (37,244 | ) | | | | | | (37,244 | ) | | | | | (37,420 | ) | | | | | | (37,420 | ) |
Balance, December 31, 2016 | 19,455 |
| | $ | 19 |
| | $ | 389,048 |
| | $ | (40,357 | ) | | $ | (1,484 | ) | | $ | 347,226 |
| |
Balance, December 31, 2017 | | 19,538 |
| | $ | 20 |
| | $ | 374,366 |
| | $ | (38,629 | ) | | $ | (2,198 | ) | | $ | 333,559 |
|
Net income | | | | | 33,728 |
| | | | | | 33,728 |
| | | | | 10,915 |
| | | | | | 10,915 |
|
Other comprehensive loss, (net of tax $89) | | | | | | | | | (220 | ) | | (220 | ) | |
Other comprehensive loss, (net of tax $243) (a) | | | | | | | | | | 389 |
| | 389 |
|
Effects of U.S. enacted Tax Cuts and Jobs Act (a) | | | | | | (293 | ) | | | | | | (293 | ) |
Effects of adoption of ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory | | | | | | 360 |
| | | | | | 360 |
|
Proceeds from stock award exercises and issuances | 87 |
| | 1 |
| | | | (1,092 | ) | | | | (1,091 | ) | 5 |
| | | | | | (54 | ) | | | | (54 | ) |
Share-based compensation | | | | | | | 2,996 |
| | | | 2,996 |
| | | | | | | 998 |
| | | | 998 |
|
Restricted stock forfeitures | (13 | ) | | | | | | (738 | ) | | | | (738 | ) | (7 | ) | | | | | | (251 | ) | | | | (251 | ) |
Dividends declared | | | | | (28,131 | ) | | | | | | (28,131 | ) | | | | | (9,410 | ) | | | | | | (9,410 | ) |
Balance, September 30, 2017 | 19,529 |
| | $ | 20 |
| | $ | 394,645 |
| | $ | (39,191 | ) | | $ | (1,704 | ) | | $ | 353,770 |
| |
Balance, March 31, 2018 | | 19,536 |
| | $ | 20 |
| | $ | 375,938 |
| | $ | (37,936 | ) | | $ | (1,809 | ) | | $ | 336,213 |
|
(a) Includes the impact of ASU 2018-02, which transferred those amounts from accumulated other comprehensive income (loss) to retained earnings. See Notes 1 and 17 to the Consolidated Financial Statements.
See notes to condensed consolidated financial statements
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)
1. Basis of Statement Presentation
Summary of Significant Accounting Policies
The accompanying unaudited condensed consolidated financial statements of Innophos have been prepared in accordance with generally accepted accounting principles in the United States of America (US GAAP)("US GAAP") for interim financial reporting and do not include all disclosures required by US GAAP for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 20162017 and for the three years then ended.
The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year-end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 20162017 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP.
Recently Issued Accounting Standards
Adopted
In July 2015, the FASB issued guidance which requires entities to measure most inventory “at the lower of cost and net realizable value (“NRV”),” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is “measured at the lower of cost and net realizable value,” which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The guidance is effective for annual periods beginning after December 15, 2016, and interim periods therein. Early application is permitted. The adoption of this standard did not have a material impact on our financial position, results of operations and related disclosures.
In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends Accounting Standards Codification ("ASC") Topic 718, Compensation - Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. The adoption of this standard did not have a material impact on our financial position, results of operations and related disclosures.
In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted on testing dates after January 1, 2017. We have elected to early adopt for testing dates after January 1, 2017 and the adoption of this standard did not have a material impact on our financial position, results of operations and related disclosures.
Issued but not yet adopted
In May 2014, the FASBFinancial Accounting Standards Board ("FASB") issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In July 2015, the FASB approved the deferral of the effective date of this guidance by one year (with an option to early adopt at the original effective date), making it effective for the interim and annual periods beginning on or after December 15, 2017. As a result, this guidance will be effective for the Company beginning in fiscal year 2018, with an option to early adopt in fiscal year 2017. The guidance permits the use of
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
either a retrospective or modified retrospective transition method. We will adoptThe Company adopted the standard using the modified retrospective transition method on January 1, 2018. Based on the results of the assessment performed to date, theThe Company has preliminarily concluded that revenues are expected to remain substantiallymaterially unchanged from the currentprior revenue recognition model. The Company will continue to assessmodel and therefore, the newadoption of this standard and the potentialdid not have a material impact to ouron its financial position, results of operations and related disclosures.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet Please see Note 3, "Revenues", for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. While we are continuing to assess the effect of adoption, we currently believe the most significant changes relate to the recognition of new right-of-use assets and lease liabilities on our balance sheet for railcar and tank operating leases. We will continue to evaluate the impact of adoption of the ASU on our financial position, results of operations and relatedfurther disclosures.
In March 2016, the FASB issued ASU 2016-15, Clarification on Classification of Certain Cash Receipts and Cash Payments on the Statement of Cash Flows. ASU 2016-15 clarifies the classification of certain cash receipts and cash payments in the statement of cash flows, including debt prepayment or extinguishment costs, settlement of contingent consideration arising from a business combination, insurance settlement proceeds, and distributions from certain equity method investees. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. We are evaluating theThe Company's adoption of this standard did not have a material impact on its financial position, results of adopting this new accounting guidance on our consolidated financial statements.operations and related disclosures.
In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which reduces the complexity in the accounting standards by allowing the recognition of current and deferred income taxes for an intra-entity asset transfer, other than inventory, when the transfer occurs. Historically, recognition of the income tax consequence was not recognized until the asset was sold to an outside party. This amendment should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. There are no new disclosure requirements. This ASU is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted in the first interim period of 2017. We are currentlyThe Company adopted this standard as of January 1, 2018 on a modified retrospective basis in the process of evaluating the impact of adoption of the ASU on our financial position, results of operationsthis interim period and related disclosures.recorded an immaterial cumulative adjustment to retained earnings.
In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which clarifies guidance on the classification and presentation of restricted cash in the statement of cash flows. Under the ASU, changes in restricted cash and restricted cash equivalents would be included along with those of cash and cash equivalents in the statement of cash flows. As a result, entities
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
would no longer present transfers between cash/equivalents and restricted cash/equivalents in the statement of cash flows. In addition, a reconciliation between the balance sheet and the statement of cash flows would be disclosed when the balance sheet includes more than one line item for cash/equivalents and restricted cash/equivalents. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. We do not anticipate theThe Company's adoption of the new accounting rules willthis standard did not have a material impact on ourits financial position, results of operations and related disclosures.
In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business, which narrows the existing definition of a business and provides a framework for evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or a business. The ASU requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities (collectively, the set) is not a business. To be considered a business, the set would need to include an input and a substantive process that together significantly contribute to the ability to create outputs. The standard also narrows the definition of outputs. The definition of a business affects areas of accounting such as acquisitions, disposals and goodwill. Under the new guidance, fewer acquired sets are expected to be considered businesses. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. We would applyThe Company's adoption of this guidance to applicable transactions after the adoption date.standard did not have a material impact on its financial position, results of operations and related disclosures.
In March 2017, the FASB issued ASU No. 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic PostretirementPost-retirement Benefit Cost, which requires that only the service cost component of net periodic benefit costs be recorded as compensation cost in the operating expense section of the income statement. All other components of net periodic benefit cost (interest cost, expected return on plan assets and amortization of net loss) will be presented in other income -(loss), net.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
This standard update is effective beginning with the first quarter 2018 and must be applied retrospectively. We are evaluating theThe Company's adoption of this standard did not have a material impact on its financial position, results of adopting this new accounting guidance on our consolidated financial statements.operations and related disclosures.
In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting, which requires all modifications to be accounted for as a modification unless the fair value, vesting conditions and classification of the award as equity or liability are the same as the classification of the original award immediately before the original award is modified. The amendments in this ASU are effective for fiscal years beginning after December 15, 2017 and for interim periods therein. The Company's adoption of this guidance isstandard did not expected to have a material impact on its financial position, results of operations and related disclosures.
In March 2018, the FASB issued ASU 2018-05 associated with the accounting and disclosures around the enactment of the Act and the Securities and Exchange Commission’s Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which the Company has adopted. See Note 14 for the disclosures related to this amended guidance.
Issued but not yet adopted
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. While the Company is continuing to assess the effect of adoption, it currently believes the most significant effectchanges relate to the recognition of new right-of-use assets and lease liabilities on ourits balance sheet for railcar and tank operating leases. The Company will continue to evaluate the impact of adoption of the ASU on its financial position, results of operations and related disclosures.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and hedging (Topic 815): Targeted improvements to accounting for hedging activities. This standard more closely aligns the results of cash flow and fair value hedge accounting with risk management activities through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results in the financial statements. This standard also addresses specific limitations in current GAAP by expanding hedge accounting for both nonfinancial and financial risk components and by refining the measurement of hedge results to better reflect an entity’s hedging strategies. Additionally, by aligning the timing of recognition of hedge results with the earnings effect of the hedged item for cash flow and net investment hedges, and by including the earnings effect of the hedging instrument in the same income statement line item in which the earnings effect of the hedged item is presented, the results of an entity’s hedging program and the cost of executing that program will be more visible to users of financial statements. The new standard is effective for annual reporting periods beginning after December 15, 2018 with early adoption permitted. We do not anticipate the adoption of this standard will have a material impact on our financial position, results of operations and related disclosures.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
early adoption permitted. The Company does not anticipate the adoption of this standard will have a material impact on its financial position, results of operations and related disclosures.
2. Acquisitions
On August 25, 2017, the Company acquired 100 percent100% of the outstanding shares of GenNx Novel Holding, Inc. (together with its direct and indirect wholly-owned subsidiaries, "Novel Ingredients"). Novel Ingredients was a privately-held specialty ingredients supplier of botanicals, proteins, amino acids and other healthy ingredients, as well as branded ingredient and custom formulated solutions, headquartered in East Hanover, NJ. The Company made aan initial $125 million cash payment, subject tosubsequently adjusted lower by $1.3 million for post-closing working capital adjustments, whichfor total consideration of $123.7 million. The acquisition was funded by borrowings under its existing credit facility. The addition of Novel Ingredients grows Innophos' Food, Health, and Nutrition ("FHN") portfolio, expanding its presence in high-growth nutrition end-markets and positioning the Company to more effectively develop innovative ingredient solutions that better serve its customers. Novel Ingredients serves attractive end-markets driven by health and wellness consumer trends such as immune health, sports nutrition, and cognitive health.
On November 3, 2017, the Company acquired 100% of the outstanding equity interests of NutraGenesis LLC, Icon Group LLC, and Tradeworks Group, Inc. (collectively referred to as "NutraGenesis"). NutraGenesis was a privately-held Vermont-based marketer of proprietary, branded and science-backed nutraceutical ingredients. The Company made a $27.4 million cash payment, subject to post-closing working capital adjustments, which was funded by borrowings under its existing credit facility. NutraGenesis is highly complementary to the Novel Ingredients acquisition and the Company's branded ingredients portfolio. NutraGenesis serves attractive high-growth end-markets, including stress reduction, weight management, joint health, brain health and metabolic wellness, that are driven by health and wellness consumer trends.
During the three months ended September 30, 2017,March 31, 2018, the Company's results of operations included revenues of $10.2$33.6 million and a $0.6$0.9 million net lossincome attributable to Novel Ingredients. Acquisition related costs of $2.4 million (excluding integration costs of $0.6 million) were expensed as incurredIngredients and were included in selling, general and administrative expenses.NutraGenesis.
The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition and will be included in the Food, Health and Nutrition operating segment. The goodwill of $55.1$68.3 million arising from the acquisitionacquisitions consists of expected revenue and cost synergies, operational know-how, and acquired workforce. Approximately $24.0 million of the goodwill is deductible for U.S. income tax purposes.
The following table summarizes the estimated fair value of the assets acquired and liabilities assumed (in thousands):
| | | Novel Ingredients | Novel Ingredients | | NutraGenesis |
Cash | $ | 105 |
| $ | 105 |
| | $ | 82 |
|
Accounts receivable, net of allowances of $319 | 11,447 |
| |
Inventory, including fair value adjustment of $4,300 | 23,121 |
| |
Accounts receivable, net of allowances of $511 and $0 for Novel Ingredients and NutraGenesis, respectively | | 11,255 |
| | 850 |
|
Inventory, including fair value adjustment of $4,300 for Novel Ingredients | | 23,121 |
| | — |
|
Other current assets | 1,655 |
| 1,655 |
| | 638 |
|
Property, plant and equipment | 4,261 |
| 4,261 |
| | — |
|
Other non-current assets | 187 |
| 187 |
| | — |
|
Goodwill | 55,086 |
| 54,008 |
| | 14,320 |
|
Intangible assets | 52,900 |
| 52,900 |
| | 13,699 |
|
Accounts payable | (15,854 | ) | (14,726 | ) | | (793 | ) |
Accrued expenses | (2,782 | ) | (3,910 | ) | | (524 | ) |
Deferred income taxes | (5,037 | ) | (5,067 | ) | | — |
|
Customer Deposits | | — |
| | (875 | ) |
Total | $ | 125,089 |
| $ | 123,789 |
| | $ | 27,397 |
|
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
In preparing the preliminary fair value estimates of the intangible assets and certain tangible assets acquired, management consulted with an independent third party. The purchase price and related allocation to assets acquired and liabilities assumed is preliminary pending finalization of the fair values assigned to the intangible assets and the valuation of the working capital components acquired as of the acquisition date.
From previous asset acquisitions, Novel Ingredients has amortizable goodwill and intangible assets that will continue to provide tax amortization deductions in future years. However, the excess of purchase price over the corresponding tax basis resulting from this acquisition will not be deductible for tax purposes. In addition, Novel Ingredients has Net Operating Loss ("NOL") carryforwards of $16.4 million that are expected to be utilized in future periods. The deferred income tax balances are preliminary pending management's final analysis and preparation of the final period tax return.
The intangible assets acquired with Novel Ingredients and NutraGenesis include the following (in thousands):
|
| | | | | | | | | |
| Useful life (years) | | Novel Ingredients | | NutraGenesis |
Customer relationships | 15-20 | | $ | 46,200 |
| | $ | 10,499 |
|
Trade names | 5-10 | | 6,700 |
| | 3,200 |
|
| | | $ | 52,900 |
| | $ | 13,699 |
|
The weighted average useful life (years) of the intangible assets included in the above table is 17.4 years. The weighted average useful life (years) of the trade names included in the above table is 7.9 years. The weighted average useful life (years) of the customer relationships included in the above table is 19.1 years.
The three months ended March 31, 2018 includes non-recurring integration costs of approximately $0.8 million in selling, general and administrative expense.
3. Revenue Recognition
Adoption of ASC Topic 606, "Revenue from Contracts with Customers"
On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Based on the results of the analysis performed on the Company's effective contracts as of the initial application, the Company has concluded that revenues are expected to remain substantially unchanged from the previous revenue recognition model, and therefore, the adoption of the new standard does not have a material impact on the Company's financial position, results of operations or related disclosures.
Revenue Recognition
Revenues are recognized when control of goods is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods. Control passes either upon shipment or delivery, depending on the agreed sales terms with customers.
Certain customers may receive cash-based incentives or credits, which are accounted for as variable consideration. The Company estimates these amounts based on the expected amount to be provided to customers and reduce revenues recognized. The Company believes there will not be significant changes to its estimates of variable consideration.
The Company reports its business in three operating segments: Food, Health, and Nutrition; Industrial Specialties; and Other. The Company has three principal product lines within these operating segments: (i) Specialty Ingredients; (ii) Core Ingredients; and (iii) Co-Products and Other. Revenue recognition is measured on the same basis across these segments, products, markets, and geographic countries, with the performance obligation being the transfer of control of goods at a single point in time.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
|
| | | | | | | | | | | | | | | |
| Quarter Ended March 31, 2018 |
| U.S. | Canada | Mexico | Other Countries | Total |
Specialty Products | $ | 114,784 |
| $ | 5,838 |
| $ | 7,617 |
| $ | 19,404 |
| $ | 147,643 |
|
Core Ingredients | 16,415 |
| 2,000 |
| 17,643 |
| 9,759 |
| 45,817 |
|
Co-Products & Other | 8,707 |
| 65 |
| 3,208 |
| — |
| 11,980 |
|
Total | $ | 139,906 |
| $ | 7,903 |
| $ | 28,468 |
| $ | 29,163 |
| $ | 205,440 |
|
|
| | | | | | | | | | | | | | | |
| Quarter Ended March 31, 2017 |
| U.S. | Canada | Mexico | Other Countries | Total |
Specialty Products | $ | 81,817 |
| $ | 5,109 |
| $ | 7,636 |
| $ | 17,346 |
| $ | 111,908 |
|
Core Ingredients | 15,095 |
| 2,084 |
| 18,613 |
| 7,256 |
| 43,048 |
|
Co-Products & Other | 3,813 |
| 66 |
| 2,305 |
| 4,804 |
| 10,988 |
|
Total | $ | 100,725 |
| $ | 7,259 |
| $ | 28,554 |
| $ | 29,406 |
| $ | 165,944 |
|
Revenues for the geographic information are attributed to geographic areas based on the destination of the sale.
The intangible assets acquiredCompany's payment terms vary by geography and location of its customer and the products offered. Invoices are generated upon shipment of the goods, with Novelthe term between invoicing and when payment is due being insignificant.
Food, Health, and Nutrition and Industrial Specialties
The Food, Health and Nutrition reporting segment, as well as the Industrial Specialties reporting segment, consists of products in the Specialty Ingredients includeand Core Ingredients product lines.
Specialty Ingredients are the following (in thousands):most value adding products in the Company's portfolio. Specialty Ingredients consist of specialty phosphate products, specialty phosphoric acids, including polyphosphoric acid, and a range of other mineral, enzyme and botanical based specialty ingredients. The Company's Specialty Ingredients products have a wide range of applications, such as flavor enhancers in beverages, electrolytes in sports drinks, and excipients in vitamins, minerals, nutritional supplements and pharmaceuticals, among others.
The Company's Core Ingredients product line includes food grade purified phosphoric acid ("PPA"), technical grade PPA, sodium tripolyphosphate ("STPP"), and detergent grade PPA. Food grade PPA can be used to produce phosphate salts and has a variety of applications in food and beverages. Technical grade PPA has applications in water treatment. The Company also sells technical grade PPA in the merchant market to third-party phosphate derivative producers. STPP is a key ingredient in cleaning products, including industrial and institutional cleaners and automatic dishwashing detergents and consumer laundry detergents outside the United States. In addition to its use in cleaning products, STPP is also used in water treatment, clay processing, and copper ore processing. The end use market for STPP is largely derived from consumer product applications. Detergent Grade PPA is a lower grade form of PPA used primarily in the production of STPP.
Other
The Other reporting segment consists of products in the Co-Products and Other product line.
The Company's Co-Products and Other product line includes granular triple super phosphate ("GTSP"), and merchant green phosphoric acid ("MGA"). GTSP is generated at the Company's Coatzacoalcos facility in Mexico as a co-product of its purified wet acid manufacturing process. GTSP is a fertilizer product used throughout Latin America for increasing crop yields in a wide range of agricultural sectors. The Company sells MGA in the merchant market to third party manufacturers of fertilizer products.
|
| | | | |
| Useful life (years) | Novel Ingredients |
Customer relationships | 20 | $ | 46,200 |
|
Trade name | 5-10 | 6,700 |
|
| | $ | 52,900 |
|
The weighted average useful life (years) of the intangible assets included in the above table is 18.4 years. The weighted average useful life (years) of the trade names included in the above table is 7.5 years.INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
The following unaudited pro forma information has been prepared as if the acquisition had occurred on January 1, 2016 (amountsNotes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, excluding EPS figures). The unaudited pro forma results do not reflect any material adjustments, operating efficiencies and other synergies which may result from the consolidation of operations.except per share amounts, share amounts or where otherwise noted)
Practical Expedients and Exemptions |
| | | | | | | | | | | | |
| Three Months Ended September 30, | Nine Months Ended September 30, |
| 2017 | 2016 | 2017 | 2016 |
Revenues | $ | 196,873 |
| $ | 205,023 |
| $ | 588,331 |
| $ | 616,489 |
|
Net income | $ | 9,229 |
| $ | 12,744 |
| $ | 31,165 |
| $ | 32,456 |
|
Income per common share - Basic | $ | 0.48 |
| $ | 0.66 |
| $ | 1.61 |
| $ | 1.69 |
|
Income per common share - Diluted | $ | 0.47 |
| $ | 0.65 |
| $ | 1.58 |
| $ | 1.66 |
|
These amounts have been calculated after applyingManagement reviewed the Company's accounting policies and adjustingpractical expedients which a Company may utilize when implementing Topic 606. As such, the results of Novel Ingredients to reflectCompany has applied the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had been applied on January 1, 2016. Interest expensepractical expedient related to significant financing components and does not disclose the borrowingvalue of unsatisfied performance obligations for the acquisition was applied on January 1, 2016. Depreciation and amortizationcontracts with an original expected length of approximately $3.0 million and interest expense of approximately $2.6 million related to the above were included in the nine months ended September 30, 2017 and September 30, 2016. Further, the above pro forma amounts include a fair value adjustment to inventory of $4.3 million and was applied on January 1, 2016. The three and nine months ended September 30, 2017 include non-recurring transaction costs of approximately $2.4 million.
one year or less.
3.4. Earnings per Share (EPS)
The Company accounts for earnings per share in accordance with ASC 260, which requires two calculations of earnings per share (EPS)("EPS") to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as ourthe Company's restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.
The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:
| | | Three Months Ended | | Nine Months Ended | Three Months Ended |
| September 30, 2017 | | September 30, 2016 | | September 30, 2017 | | September 30, 2016 | March 31, 2018 | | March 31, 2017 |
Net income | $ | 11,582 |
| | $ | 13,643 |
| | $ | 33,728 |
| | $ | 38,589 |
| $ | 10,915 |
| | $ | 10,923 |
|
Less: earnings attributable to unvested shares | (69 | ) | | (95 | ) | | (188 | ) | | (233 | ) | (22 | ) | | (50 | ) |
Net income available to participating common shareholders | $ | 11,513 |
| | $ | 13,548 |
| | $ | 33,540 |
| | $ | 38,356 |
| $ | 10,893 |
| | $ | 10,873 |
|
Weighted average number of participating common and potential common shares outstanding: | | | | | | | | | | |
Basic number of participating common shares outstanding | 19,412,474 |
| | 19,294,070 |
| | 19,395,317 |
| | 19,255,143 |
| 19,501,346 |
| | 19,376,258 |
|
Dilutive effect of stock equivalents | 286,578 |
| | 376,089 |
| | 300,213 |
| | 316,860 |
| 209,766 |
| | 318,493 |
|
Diluted number of weighted average participating common shares outstanding | 19,699,052 |
| | 19,670,159 |
| | 19,695,530 |
| | 19,572,003 |
| 19,711,112 |
| | 19,694,751 |
|
Earnings per participating common share: | | | | | | | | | | |
Earnings per participating common share—Basic | $ | 0.59 |
| | $ | 0.70 |
| | $ | 1.73 |
| | $ | 1.99 |
| $ | 0.56 |
| | $ | 0.56 |
|
Earnings per participating common share—Diluted | $ | 0.58 |
| | $ | 0.69 |
| | $ | 1.70 |
| | $ | 1.96 |
| $ | 0.55 |
| | $ | 0.55 |
|
| | | | | | | | | | |
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive | 395,850 |
| | 461,193 |
| | 382,215 |
| | 520,422 |
| 383,380 |
| | 347,354 |
|
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
4.5. Dividends
The following is the dividend activity for the three and nine months ended September 30, 2017March 31, 2018 and September 30, 2016March 31, 2017:
| | | Three Months Ended | | Nine Months Ended | Three Months Ended |
| September 30 | | September 30 | March 31 |
| 2017 |
| 2016 | | 2017 | | 2016 | 2018 |
| 2017 |
Dividends declared – per share | $ | 0.48 |
| | $ | 0.48 |
| | $ | 1.44 |
| | $ | 1.44 |
| $ | 0.48 |
| | $ | 0.48 |
|
Dividends declared – aggregate | 9,373 |
| | 9,327 |
| | 28,095 |
| | 27,891 |
| 9,380 |
| | 9,349 |
|
Dividends paid – per share | 0.48 |
| | 0.48 |
| | 1.44 |
| | 1.44 |
| 0.48 |
| | 0.48 |
|
Dividends paid – aggregate | 9,373 |
| | 9,327 |
| | 28,095 |
| | 27,891 |
| 9,380 |
| | 9,349 |
|
Innophos Holdings, Inc. is a holding company that does not conduct any business operations of its own. As a result, it is dependent upon cash dividends, distributions and other transfers from its subsidiaries, most directly Innophos, Inc., its primary operating subsidiary, and Innophos Investments Holdings, Inc., a direct, wholly-owned subsidiary of Innophos Holdings, Inc. and the direct parent company of Innophos, Inc., to make dividend payments on its common stock.
6. Stockholders’ Equity / Stock-Based Compensation
The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:
|
| | | | | | | |
| Three Months Ended |
| March 31, 2018 | | March 31, 2017 |
Stock options | $ | 346 |
| | $ | 305 |
|
Restricted stock | 525 |
| | 440 |
|
Performance shares | 127 |
| | (28 | ) |
Total share-based compensation expense | $ | 998 |
| | $ | 717 |
|
7. Inventories
Inventories consist of the following:
|
| | | | | | | |
| March 31, 2018 | | December 31, 2017 |
Raw materials | $ | 50,583 |
| | $ | 48,445 |
|
Finished products | 90,262 |
| | 83,634 |
|
Spare parts | 13,629 |
| | 13,606 |
|
| $ | 154,474 |
| | $ | 145,685 |
|
Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of March 31, 2018 and December 31, 2017 were $14,883 and $16,168, respectively.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
8. Other Current Assets
Other current assets consist of the following:
|
| | | | | | | |
| March 31, 2018 | | December 31, 2017 |
Creditable taxes (value added taxes) | $ | 7,141 |
| | $ | 7,285 |
|
Vendor inventory deposits (prepaid) | 10,979 |
| | 7,807 |
|
Prepaid income taxes | 3,317 |
| | 3,394 |
|
Prepaid insurance | 1,800 |
| | 2,492 |
|
Other | 1,435 |
| | 3,991 |
|
| $ | 24,672 |
| | $ | 24,969 |
|
9. Goodwill
The following table provides a reconciliation of the carrying amount of goodwill at the beginning and end of the reporting period (in thousands):
|
| | | | | | | | | | | | |
| Food, Health and Nutrition | Industrial Specialties | Other | Total |
Balance: January 1, 2018 | $ | 129,417 |
| $ | 23,283 |
| $ | — |
| $ | 152,700 |
|
Add: Goodwill from acquisition | — |
| — |
| — |
| — |
|
Balance: March 31, 2018 | $ | 129,417 |
| $ | 23,283 |
| $ | — |
| $ | 152,700 |
|
10. Intangibles and Other Assets, net
Intangibles and other assets consist of the following:
|
| | | | | | | | | |
| Useful life (years) | | March 31, 2018 | | December 31, 2017 |
Developed technology and application patents, net of accumulated amortization of $31,713 for 2018 and $30,716 for 2017 | 7-20 | | $ | 14,562 |
| | $ | 15,559 |
|
Customer relationships, net of accumulated amortization of $23,705 for 2018 and $22,279 for 2017 | 5-20 | | 71,806 |
| | 73,232 |
|
Trade names and license agreements, net of accumulated amortization of $12,669 for 2018 and $12,023 for 2017 | 5-20 | | 14,892 |
| | 15,538 |
|
Non-compete agreements, net of accumulated amortization of $1,300 for 2018 and $1,293 for 2017 | 3-10 | | 33 |
| | 40 |
|
Total intangibles | | | $ | 101,293 |
| | $ | 104,369 |
|
Deferred income taxes | | | $ | 5,058 |
| | $ | 5,058 |
|
Deferred financing costs, net of accumulated amortization of $4,010 for 2018 and $3,902 for 2017 (see note 12) | | | 1,613 |
| | 1,721 |
|
Other tax assets | | | — |
| | — |
|
Other assets | | | 1,981 |
| | 1,768 |
|
Total other assets | | | $ | 8,652 |
| | $ | 8,547 |
|
| | | $ | 109,945 |
| | $ | 112,916 |
|
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
5. Stockholders’ Equity / Stock-Based Compensation
Restricted Stock
In April and May 2017, there were a total of 30,612 restricted shares granted to certain employees with a fair value of $1.6 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share prices of $52.51 and $48.42 for April and May, respectively. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.
Stock Options
In April and May 2017, the Company granted a total of 102,607 non-qualified stock options at exercise prices of $52.51 and $48.42 for April and May, respectively, to certain employees with a fair value of $1.2 million. The non-qualified stock options vest annually over three years with April 3, 2027 and May 1, 2027 expiration dates.
The fair values of the options granted in 2017 were determined using the Black-Scholes option-pricing model. The blended assumptions used in the Black-Scholes option-pricing model were as follows for the April 3, 2017 and May 1, 2017 grants:
|
| | | | |
Non-qualified stock options | | |
Expected Volatility | | 31.3 | % |
Dividend Yield | | 3.6 | % |
Risk-free interest rate | | 2.09 | % |
Expected term (years) | | 6.6 |
|
Weighted average grant date fair value of stock options | | $ | 11.54 |
|
For the 2017 grants, the expected volatility and the expected term are based on the Company's historical data. The dividend yield is the expected annual dividend payments divided by the average stock price since announcement of the latest dividend up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly.
Performance Share Awards
In April and May 2017, the Company granted 22,958 performance shares to certain employees with a fair value of $1.3 million. The performance shares vest at the end of the three years performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period.
Stock Grants
In May 2017, the seven external members of the Board of Directors were granted a combined total of 13,916 shares of the Company's common stock with an aggregated fair value of approximately $0.6 million which immediately vested as part of their director fees.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:
|
| | | | | | | | | | | | | | | |
| Three Months Ended | | Nine Months Ended |
| September 30, 2017 | | September 30, 2016 | | September 30, 2017 | | September 30, 2016 |
Stock options | $ | 221 |
| | $ | 354 |
| | $ | 825 |
| | $ | 439 |
|
Restricted stock | 378 |
| | 497 |
| | 1,290 |
| | 837 |
|
Performance shares | 112 |
| | 177 |
| | 251 |
| | 458 |
|
Stock grants | — |
| | — |
| | 630 |
| | 595 |
|
Total share-based compensation expense (a) | $ | 711 |
| | $ | 1,028 |
| | $ | 2,996 |
| | $ | 2,329 |
|
(a) The nine months ended September 30, 2016 includes a benefit of $524 for a change in estimate due to restructuring activities.
6. Inventories
Inventories consist of the following:
|
| | | | | | | |
| September 30, 2017 | | December 31, 2016 |
Raw materials | $ | 45,501 |
| | $ | 33,185 |
|
Finished products | 89,079 |
| | 81,369 |
|
Spare parts | 13,956 |
| | 13,741 |
|
| $ | 148,536 |
| | $ | 128,295 |
|
Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of September 30, 2017 and December 31, 2016 were $18,544 and $13,422, respectively.
7. Other Current Assets
Other current assets consist of the following:
|
| | | | | | | |
| September 30, 2017 | | December 31, 2016 |
Creditable taxes (value added taxes) | $ | 8,053 |
| | $ | 9,722 |
|
Vendor inventory deposits (prepaid) | 8,902 |
| | 3,750 |
|
Prepaid income taxes | 4,036 |
| | 4,659 |
|
Prepaid insurance | 2,126 |
| | 2,248 |
|
Other | 2,362 |
| | 3,515 |
|
| $ | 25,479 |
| | $ | 23,894 |
|
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
8. Goodwill
The following table provides a reconciliation of the carrying amount of goodwill at the beginning and end of the reporting period (in thousands):
|
| | | | | | | | | | | | |
| Food, Health and Nutrition | Industrial Specialties | Other | Total |
Balance: January 1, 2017 | $ | 61,090 |
| $ | 23,283 |
| $ | — |
| $ | 84,373 |
|
Add: Goodwill from acquisition | 55,086 |
| — |
| — |
| 55,086 |
|
Balance: September 30, 2017 | $ | 116,176 |
| $ | 23,283 |
| $ | — |
| $ | 139,459 |
|
9. Intangibles and Other Assets, net
Intangibles and other assets consist of the following:
|
| | | | | | | | | |
| Useful life (years) | | September 30, 2017 | | December 31, 2016 |
Developed technology and application patents, net of accumulated amortization of $29,891 for 2017 and $27,778 for 2016 | 7-20 | | $ | 16,294 |
| | $ | 18,497 |
|
Customer relationships, net of accumulated amortization of $20,881 for 2017 and $18,569 for 2016 | 5-20 | | 64,131 |
| | 20,243 |
|
Trade names and license agreements, net of accumulated amortization of $11,410 for 2017 and $10,315 for 2016 | 5-20 | | 12,951 |
| | 7,346 |
|
Non-compete agreements, net of accumulated amortization of $1,287 for 2017 and $1,268 for 2016 | 3-10 | | 46 |
| | 65 |
|
Total intangibles | | | $ | 93,422 |
| | $ | 46,151 |
|
Deferred income taxes | | | $ | 13,430 |
| | $ | 18,432 |
|
Deferred financing costs, net of accumulated amortization of $3,795 for 2017 and $3,473 for 2016 (see note 11) | | | 1,828 |
| | 2,150 |
|
Other tax assets | | | — |
| | 997 |
|
Other assets | | | 2,117 |
| | 2,081 |
|
Total other assets | | | $ | 17,375 |
| | $ | 23,660 |
|
| | | $ | 110,797 |
| | $ | 69,811 |
|
10.11. Other Current Liabilities
Other current liabilities consist of the following:
|
| | | | | | | |
| September 30, 2017 | | December 31, 2016 |
Payroll related | $ | 13,696 |
| | $ | 11,852 |
|
Taxes other than income taxes | 1,652 |
| | 2,624 |
|
Benefits and pensions | 5,687 |
| | 5,419 |
|
Freight and rebates | 3,754 |
| | 3,579 |
|
Income taxes | 11,695 |
| | 9,278 |
|
Restructuring and management transition reserve | 2,165 |
| | 4,737 |
|
Other | 9,296 |
| | 6,116 |
|
| $ | 47,945 |
| | $ | 43,605 |
|
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
|
| | | | | | | |
| March 31, 2018 | | December 31, 2017 |
Payroll related | $ | 10,248 |
| | $ | 15,684 |
|
Taxes other than income taxes | 1,571 |
| | 2,804 |
|
Benefits and pensions | 5,058 |
| | 7,730 |
|
Freight and rebates | 6,004 |
| | 3,937 |
|
Income taxes | 7,102 |
| | 4,933 |
|
Restructuring and management transition reserve | 253 |
| | 1,719 |
|
Other | 7,064 |
| | 6,277 |
|
| $ | 37,300 |
| | $ | 43,084 |
|
11.12. Short-Term Borrowings, Long-Term Debt, and Interest Expense
Short-term borrowings and long-term debt consist of the following:
| | | September 30, 2017 | | December 31, 2016 | March 31, 2018 | | December 31, 2017 |
Revolver borrowings under the credit facility due 2021 | $ | 295,000 |
| | $ | 185,000 |
| $ | 345,000 |
| | $ | 310,000 |
|
Capital leases | 10 |
| | — |
| 8 |
| | 9 |
|
Total borrowings | $ | 295,010 |
| | $ | 185,000 |
| $ | 345,008 |
| | $ | 310,009 |
|
Less current portion of capital leases | 4 |
| | — |
| 4 |
| | 4 |
|
Long-term debt | $ | 295,006 |
| | $ | 185,000 |
| $ | 345,004 |
| | $ | 310,005 |
|
The Company's credit facility includes a revolving line of credit from the lenders of up to $450.0 million, including a $20.0 million letter of credit sub-facility and a $20.0 million swingline loan facility, all maturing on December 22, 2021. The credit agreement governing this facility also provides for possible additional revolving indebtedness under an incremental facility of up to $150.0 million (for an aggregate of revolving capacity up to $600.0 million) upon future request by the Company to existing lenders (and depending on their consent) or from other willing financial institutions invited by the Company and reasonably acceptable to the administrative agent to join in the credit agreement. This revolving credit facility increase, if implemented, may provide for higher applicable margins to either the increased portion or possibly the entire revolving credit facility, with limitations, than those in effect for the original revolving commitments under the credit agreement.
As of September 30, 2017March 31, 2018, $295.0$345.0 million was outstanding under the revolving line of credit, which approximates fair value (determined using level 2 inputs within the fair value hierarchy) with total availability at $153.9$103.9 million, taking into account $1.1 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 2.8%4.0%.
Among its affirmative covenants, the credit agreement governing this credit facility requires the Company to maintain the following consolidated ratios (as defined and calculated according to the credit agreement) as of the end of each fiscal quarter:
(a) “Total Leverage Ratio” less than or equal to 3.50 to 1.00.
(b) “Interest Coverage Ratio” greater than or equal to 3.00 to 1.00.
As of September 30, 2017,March 31, 2018, the Company was in full compliance with all debt covenant requirements.
In December 2012, Innophos entered into an interest rate swap, swapping the LIBOR exposure on $100.0 million floating rate debt, which is currently outstanding under the credit agreement, to a fixed rate to maturity obligation of 0.9475% expiring in December 2017. This interest rate swap has been designated as a cash flow hedge (Level 2) with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap of approximately $0.1 million is recorded in other long-term assets as of September 30, 2017. Based on $195.0$345.0 million outstanding borrowings as floating rate debt, (amount not covered by the swap), an immediate increase of one percentage point would cause an increase to interest expense of approximately $2.0$3.5 million per year.
We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.
Total interest paid by the Company for all indebtedness for the nine months ended September 30, 2017 and September 30, 2016 was $4.3 million and $5.3 million, respectively.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
Total interest paid by the Company for all indebtedness for the three months ended March 31, 2018 and March 31, 2017 was $3.1 million and $1.3 million, respectively.
Interest expense, net consists of the following:
| | | Three months ended | | Nine months ended | Three months ended |
| September 30, 2017 | | September 30, 2016 | | September 30, 2017 | | September 30, 2016 | March 31, 2018 | | March 31, 2017 |
Interest expense | $ | 1,667 |
| | $ | 1,796 |
| | $ | 4,432 |
| | $ | 5,297 |
| $ | 3,096 |
| | $ | 1,315 |
|
Deferred financing cost | 107 |
| | 168 |
| | 322 |
| | 505 |
| 108 |
| | 107 |
|
Interest income | (21 | ) | | (14 | ) | | (41 | ) | | (38 | ) | (20 | ) | | (9 | ) |
Less: amount capitalized for capital projects | (123 | ) | | (35 | ) | | (278 | ) | | (137 | ) | (280 | ) | | (60 | ) |
Total interest expense, net | $ | 1,630 |
| | $ | 1,915 |
| | $ | 4,435 |
| | $ | 5,627 |
| $ | 2,904 |
| | $ | 1,353 |
|
12.13. Other Long-Term Liabilities
Other long-term liabilities consist of the following:
| | | September 30, 2017 | | December 31, 2016 | March 31, 2018 | | December 31, 2017 |
Deferred income taxes | $ | 467 |
| | $ | 1,282 |
| $ | 2,111 |
| | $ | 2,354 |
|
Long term portion of U.S. transition tax | | 12,095 |
| | 12,095 |
|
Pension and post retirement liabilities | 8,979 |
| | 7,689 |
| 9,287 |
| | 8,886 |
|
Restructuring and management transition reserve | 210 |
| | 1,618 |
| — |
| | 210 |
|
Uncertain tax positions | 1,974 |
| | 1,974 |
| 1,094 |
| | 1,974 |
|
Environmental liabilities | 1,100 |
| | 1,100 |
| 1,100 |
| | 1,100 |
|
Other liabilities | 1,342 |
| | 1,906 |
| 1,572 |
| | 1,453 |
|
| $ | 14,072 |
| | $ | 15,569 |
| $ | 27,259 |
| | $ | 28,072 |
|
13.14. Income Taxes
The effective income tax rate on income before taxes was approximately 32%30% for the ninethree months ended September 30, 2017March 31, 2018 compared to approximately 32%28% for the comparable period in 2016.2017. The change in the components of the effective tax rate are primarily due to the adoptionenactment of ASU No. 2016-09, Improvementsthe Tax Act and changes in excess tax benefit from stock-based compensation. The reduction in the statutory U.S. Federal corporate tax rate and a change of mix of U.S. to Employee Share-Based Payment Accounting, changingforeign earnings resulted in an 8% decrease in the accounting foreffective tax benefits from stock option exercises and vesting of restricted stock and performance awards, which decreasedrate. This was offset by the incremental U.S. tax on global intangible low-taxed income (“GILTI”) resulting in an increase to the effective tax rate by 2%,4%. Further, the rate increased 5% resulting from a permanent adjustment attributablesmaller excess tax benefit from stock-based compensation.
On December 22, 2017, the U.S. enacted the Tax Act. The Tax Act significantly changes U.S. corporate income tax laws by, among other things, reducing the U.S. corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017 and transitioning U.S. international taxation from a worldwide tax system to a territorial tax system.
Beginning in 2018, the Tax Act includes two new U.S. provisions, namely the GILTI provisions and the base-erosion and anti-abuse tax (“BEAT”) provisions.
The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an inventory obsolescence reserve in Mexicoallowable return on the foreign subsidiary’s tangible assets. In the first quarter of 2018, the Company elected to treat any potential GILTI inclusions as a period cost.
The BEAT provisions in the priorTax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The Company does not expect to have any material tax
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
impacts of BEAT and therefore has not recorded any related tax impacts in its consolidated financial statements for the period ended March 31, 2018.
On December 22, 2017, the Securities and Exchange Commission issued SAB 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118 and ASU 2018-05, the Company has recognized the provisional tax impacts related to the re-measurement of our deferred income tax assets and liabilities and the one-time, mandatory transition tax on deemed repatriation during the year which decreasedended December 31, 2017. As of March 31, 2018, we have not made any additional measurement-period adjustments related to these items. Such adjustments may be necessary in future periods due to, among other things, the effective tax ratesignificant complexity of the Act and anticipated additional regulatory guidance that may be issued by 1%the Internal Revenue Service (“IRS”), changes in analysis, interpretations and assumptions the Company has made and actions the Company may take as compareda result of the Act. Any subsequent adjustment to lastthese amounts will be recorded within the one year and prior year tax return true-ups which increased the effective tax ratemeasurement period allowed by 3% as compared to last year.SAB 118.
Business is conducted in various countries throughout the world and is subject to tax in numerous jurisdictions. A significant number of tax returns are filed and subject to examination by various federal, state and local tax authorities. Tax examinations are often complex, as tax authorities may disagree with the treatment of items reported requiring several years to resolve. As such, the Company maintains liabilities for possible assessments by tax authorities resulting from known tax exposures for uncertain income tax positions. The Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination on income tax returns, for the years 2009 through 2015. Also, certain state income tax assessments are under protest and the Company believes its financial position is sustainable. The Company estimates the liability for unrecognized tax benefits may decrease by approximately $0.7$2.4 million during the next twelve months as a result of possible settlements of income tax authority examinations. Other than the items mentioned above, as of September 30, 2017,March 31, 2018, no material adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.
Income taxes paid were $14.03.4 million and $34.85.4 million for the ninethree months ended September 30, 2017March 31, 2018 and September 30, 2016March 31, 2017, respectively.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
14.15. Commitments and Contingencies
Environmental
The Company's operations are subject to extensive and changing federal, state, local and international environmental laws, rules and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.
Environmental efforts are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. Other than the items listed below, the Company is not aware of material environmental liabilities which are probable and estimable. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.
Future environmental spending is probable at ourthe Company's site in Nashville, TN,Tennessee, the eastern portion of which had been used historically as a landfill, and a western parcel therein, previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We haveThe Company has an estimated liability with a range of $0.9 million-$1.3 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of September 30, 2017.March 31, 2018.
Litigation
2008 RCRA Civil Enforcement - Geismar, Louisiana plantPage 18 of 34
On January 12, 2017, the Company entered into a settlement with the United States Environmental Protection Agency,
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or EPA, and the Louisiana Department of Environmental Quality, or LDEQ, with respect to certain manufacturing processes at the Company’s Geismar, Louisiana plant, including the Company’s handling of (i) filter material from an enclosed intermediate filtration step to further process merchant green phosphoric acid, or MGA, that the Company receives as raw material via pipeline from the adjacent site operated by PCS and (ii) the Company’s raffinate co-product that is separated in connection with its PPA production at the plant. The EPA and LDEQ, collectively with the United States Department of Justice, or DOJ, are collectively referred to as the Government Parties. This settlement resulted from years of negotiations between the Company and the Government Parties following inspections of the plant by the Government Parties in which they raised certain violations of the federal Resource, Conservation and Recovery Act. Prior to this settlement, in the course of discussions with the Government Parties, the EPA and the DOJ required that the Company undertake, as an interim measure, the construction of a new filter unit to replace the enclosed system and allow the removal and separate handling of the filter material. The Company built that unit, which has been operating since 2012. As part of the settlement, Innophos is implementing a deep well injection system, a solution approved by the EPA and LDEQ to handle the raffinate separated at the plant. Such system is expected to be completed by early 2018. The Company previously returned the raffinate to PCS under a long-term contract it has with PCS and can continue to do so until the Company receives the necessary approvals and permits to operate its deep well system. In connection with this settlement, the Company will pay a $1.4 million civil penalty, which is accrued in other current liabilities. The consent decree relating to this settlement was entered by the United States District Court for the Middle District of Louisiana on October 4, 2017. As such, the Company will pay the $1.4 million civil penalty on November 1, 2017.where otherwise noted)
Other Legal Matters
In addition, we arethe Company is a party to legal proceedings and contractual disputes that arise in the ordinary course of ourits business. Except as to the matters specifically discussed, management believes the likelihood that the ultimate disposition of these matters will have a material adverse effect on ourthe Company's business, results of operations, financial condition and/or cash flows is remote. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on ourthe Company's business, results of operations, financial condition, and/or cash flows.
16. Pension Plans and Postretirement Benefits
Net periodic benefit expense for the United States plans:
|
| | | | | | | | | | | | | | | | | | | | | | | |
| For the three months ended March 31, 2018 | | For the three months ended March 31, 2017 |
| Pension benefits | | Other benefits | | Total | | Pension benefits | | Other benefits | | Total |
Service cost | $ | — |
| | $ | 36 |
| | $ | 36 |
| | $ | — |
| | $ | 34 |
| | $ | 34 |
|
Interest cost | 24 |
| | 29 |
| | 53 |
| | 25 |
| | 31 |
| | 56 |
|
Expected return on assets | (38 | ) | | — |
| | (38 | ) | | (35 | ) | | — |
| | (35 | ) |
Amortization of | | | | | | | | | | | |
prior service cost | — |
| | — |
| | — |
| | — |
| | — |
| | — |
|
unrecognized (gain) loss | — |
| | (40 | ) | | (40 | ) | | — |
| | (50 | ) | | (50 | ) |
net transition obligation | — |
| | — |
| | — |
| | — |
| | — |
| | — |
|
Net periodic cost | $ | (14 | ) | | $ | 25 |
| | $ | 11 |
| | $ | (10 | ) | | $ | 15 |
| | $ | 5 |
|
| | | | | | | | | | | |
Innophos has no minimum contribution requirements and does not plan to make cash contributions for its US defined benefit pension plan in 2018.
Innophos made its entire cash contribution of $3.1 million for the US defined contribution plan during the first quarter of 2018 for the plan year 2017.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
Net periodic benefit expense for the Canadian plans:
|
| | | | | | | | | | | | | | | | | | | | | | | |
| For the three months ended March 31, 2018 | | For the three months ended March 31, 2017 |
| Pension benefits | | Other benefits | | Total | | Pension benefits | | Other benefits | | Total |
Service cost | $ | 113 |
| | $ | 16 |
| | $ | 129 |
| | $ | 94 |
| | $ | 13 |
| | $ | 107 |
|
Interest cost | 132 |
| | 15 |
| | 147 |
| | 127 |
| | 13 |
| | 140 |
|
Expected return on assets | (205 | ) | | — |
| | (205 | ) | | (201 | ) | | — |
| | (201 | ) |
Amortization of | | | | | | | | | | | |
actuarial loss (gain) | 48 |
| | 1 |
| | 49 |
| | 43 |
| | — |
| | 43 |
|
prior service cost | 13 |
| | — |
| | 13 |
| | 27 |
| | — |
| | 27 |
|
net transition obligation | — |
| | 6 |
| | 6 |
| | — |
| | 6 |
| | 6 |
|
Exchange rate changes | 118 |
| | (39 | ) | | 79 |
| | (48 | ) | | 14 |
| | (34 | ) |
Net periodic cost | $ | 219 |
| | $ | (1 | ) | | $ | 218 |
| | $ | 42 |
| | $ | 46 |
| | $ | 88 |
|
| | | | | | | | | | | |
Innophos Canada, Inc. plans to make cash contributions to its Canadian defined benefit plan of approximately $0.5 million in 2018.
17. Accumulated Other Comprehensive Income (Loss)
Changes in accumulated other comprehensive income (loss) by Component:
|
| | | | | | | | | | | |
For the three months ended March 31, 2018 | Pension and Other Postretirement Adjustments | | Changes in Fair Value of Effective Cash Flow Hedges | | Total |
Balance at December 31, 2017 | $ | (2,198 | ) | | $ | — |
| | $ | (2,198 | ) |
Other comprehensive income before reclassifications | 96 |
| | — |
| | 96 |
|
Amounts reclassified from accumulated other comprehensive income | 293 |
| | — |
| | 293 |
|
Net current period other comprehensive income | 389 |
| | — |
| | 389 |
|
Balance at March 31, 2018 | $ | (1,809 | ) | | $ | — |
| | $ | (1,809 | ) |
| | | | | |
For the three months ended March 31, 2017 | Pension and Other Postretirement Adjustments | | Changes in Fair Value of Effective Cash Flow Hedges | | Total |
Balance at December 31, 2016 | $ | (1,493 | ) | | $ | 9 |
| | $ | (1,484 | ) |
Other comprehensive (loss) income before reclassifications | (5 | ) | | 92 |
| | 87 |
|
Amounts reclassified from accumulated other comprehensive income | — |
| | — |
| | — |
|
Net current period other comprehensive (loss) income | (5 | ) | | 92 |
| | 87 |
|
Balance at March 31, 2017 | $ | (1,498 | ) | | $ | 101 |
| | $ | (1,397 | ) |
| | | | | |
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
15. Pension Plans and Postretirement Benefits
Net periodic benefit expense for the United States plans:
|
| | | | | | | | | | | | | | | | | | | | | | | |
| For the three months ended September 30, 2017 | | For the three months ended September 30, 2016 |
| Pension benefits | | Other benefits | | Total | | Pension benefits | | Other benefits | | Total |
Service cost | $ | — |
| | $ | 34 |
| | $ | 34 |
| | $ | — |
| | $ | 46 |
| | $ | 46 |
|
Interest cost | 25 |
| | 31 |
| | 56 |
| | 30 |
| | 44 |
| | 74 |
|
Expected return on assets | (35 | ) | | — |
| | (35 | ) | | (37 | ) | | — |
| | (37 | ) |
Amortization of | | | | | | | | | | | |
prior service cost | — |
| | — |
| | — |
| | — |
| | — |
| | — |
|
unrecognized (gain) loss | — |
| | (50 | ) | | (50 | ) | | 2 |
| | (13 | ) | | (11 | ) |
net transition obligation | — |
| | — |
| | — |
| | — |
| | — |
| | — |
|
Net periodic cost | $ | (10 | ) | | $ | 15 |
| | $ | 5 |
| | $ | (5 | ) | | $ | 77 |
| | $ | 72 |
|
| | | | | | | | | | | |
| For the nine months ended September 30, 2017 | | For the nine months ended September 30, 2016 |
| Pension benefits | | Other benefits | | Total | | Pension benefits | | Other benefits | | Total |
Service cost | $ | — |
| | $ | 101 |
| | $ | 101 |
| | $ | — |
| | $ | 138 |
| | $ | 138 |
|
Interest cost | 76 |
| | 92 |
| | 168 |
| | 89 |
| | 133 |
| | 222 |
|
Expected return on assets | (105 | ) | | — |
| | (105 | ) | | (109 | ) | | — |
| | (109 | ) |
Amortization of | | | | | | | | | | | |
prior service cost | — |
| | — |
| | — |
| | — |
| | — |
| | — |
|
unrecognized (gain) loss | — |
| | (149 | ) | | (149 | ) | | 6 |
| | (39 | ) | | (33 | ) |
net transition obligation | — |
| | — |
| | — |
| | — |
| | — |
| | — |
|
Net periodic cost | $ | (29 | ) | | $ | 44 |
| | $ | 15 |
| | $ | (14 | ) | | $ | 232 |
| | $ | 218 |
|
Innophos has no minimum contribution requirements and does not plan to make cash contributions for its US defined benefit pension plan in 2017.
Innophos made its entire cash contribution of $2.9 million for the US defined contribution plan during the first quarter of 2017 for the plan year 2016.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
Net periodic benefit expense for the Canadian plans:
|
| | | | | | | | | | | | | | | | | | | | | | | |
| For the three months ended September 30, 2017 | | For the three months ended September 30, 2016 |
| Pension benefits | | Other benefits | | Total | | Pension benefits | | Other benefits | | Total |
Service cost | $ | 98 |
| | $ | 13 |
| | $ | 111 |
| | $ | 92 |
| | $ | 12 |
| | $ | 104 |
|
Interest cost | 132 |
| | 14 |
| | 146 |
| | 125 |
| | 13 |
| | 138 |
|
Expected return on assets | (209 | ) | | — |
| | (209 | ) | | (195 | ) | | — |
| | (195 | ) |
Amortization of | | | | | | | | | | | |
actuarial loss (gain) | 45 |
| | — |
| | 45 |
| | 53 |
| | — |
| | 53 |
|
prior service cost | 27 |
| | — |
| | 27 |
| | 26 |
| | — |
| | 26 |
|
net transition obligation | — |
| | 6 |
| | 6 |
| | — |
| | 6 |
| | 6 |
|
Exchange rate changes | (53 | ) | | 18 |
| | (35 | ) | | 29 |
| | (9 | ) | | 20 |
|
Net periodic cost | $ | 40 |
| | $ | 51 |
| | $ | 91 |
| | $ | 130 |
| | $ | 22 |
| | $ | 152 |
|
| | | | | | | | | | | |
| For the nine months ended September 30, 2017 | | For the nine months ended September 30, 2016 |
| Pension benefits | | Other benefits | | Total | | Pension benefits | | Other benefits | | Total |
Service cost | $ | 285 |
| | $ | 38 |
| | $ | 323 |
| | $ | 272 |
| | $ | 36 |
| | $ | 308 |
|
Interest cost | 384 |
| | 41 |
| | 425 |
| | 368 |
| | 39 |
| | 407 |
|
Expected return on assets | (609 | ) | | — |
| | (609 | ) | | (577 | ) | | — |
| | (577 | ) |
Amortization of | | | | | | | | | | | |
actuarial loss (gain) | 131 |
| | — |
| | 131 |
| | 156 |
| | — |
| | 156 |
|
prior service cost | 80 |
| | — |
| | 80 |
| | 79 |
| | — |
| | 79 |
|
net transition obligation | — |
| | 17 |
| | 17 |
| | — |
| | 17 |
| | 17 |
|
Exchange rate changes | (199 | ) | | 63 |
| | (136 | ) | | (271 | ) | | 68 |
| | (203 | ) |
Net periodic cost | $ | 72 |
| | $ | 159 |
| | $ | 231 |
| | $ | 27 |
| | $ | 160 |
| | $ | 187 |
|
Innophos Canada, Inc. plans to make cash contributions to its Canadian defined benefit plan of approximately $0.5 million in 2017.
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
16. Accumulated Other Comprehensive Income (Loss)
Changes in accumulated other comprehensive income (loss) by Component:
|
| | | | | | | | | | | |
For the three months ended September 30, 2017 | Pension and Other Postretirement Adjustments | | Changes in Fair Value of Effective Cash Flow Hedges | | Total |
Balance at June 30, 2017 | $ | (1,645 | ) | | $ | 96 |
| | $ | (1,549 | ) |
Other comprehensive loss before reclassifications | (103 | ) | | (52 | ) | | (155 | ) |
Amounts reclassified from accumulated other comprehensive income | — |
| | — |
| | — |
|
Net current period other comprehensive loss | (103 | ) | | (52 | ) | | (155 | ) |
Balance at September 30, 2017 | $ | (1,748 | ) | | $ | 44 |
| | $ | (1,704 | ) |
| | | | | |
For the three months ended September 30, 2016 | Pension and Other Postretirement Adjustments | | Changes in Fair Value of Effective Cash Flow Hedges | | Total |
Balance at June 30, 2016 | $ | (2,932 | ) | | $ | (390 | ) | | $ | (3,322 | ) |
Other comprehensive income (loss) before reclassifications | 78 |
| | 204 |
| | 282 |
|
Amounts reclassified from accumulated other comprehensive income | — |
| | — |
| | — |
|
Net current period other comprehensive income (loss) | 78 |
| | 204 |
| | 282 |
|
Balance at September 30, 2016 | $ | (2,854 | ) | | $ | (186 | ) | | $ | (3,040 | ) |
| | | | | |
For the nine months ended September 30, 2017 | Pension and Other Postretirement Adjustments | | Changes in Fair Value of Effective Cash Flow Hedges | | Total |
Balance at December 31, 2016 | $ | (1,493 | ) | | $ | 9 |
| | $ | (1,484 | ) |
Other comprehensive (loss) income before reclassifications | (255 | ) | | 35 |
| | (220 | ) |
Amounts reclassified from accumulated other comprehensive income | — |
| | — |
| | — |
|
Net current period other comprehensive (loss) income | (255 | ) | | 35 |
| | (220 | ) |
Balance at September 30, 2017 | $ | (1,748 | ) | | $ | 44 |
| | $ | (1,704 | ) |
| | | | | |
For the nine months ended September 30, 2016 | Pension and Other Postretirement Adjustments | | Changes in Fair Value of Effective Cash Flow Hedges | | Total |
Balance at December 31, 2015 | $ | (2,842 | ) | | $ | 48 |
| | $ | (2,794 | ) |
Other comprehensive loss before reclassifications | (12 | ) | | (234 | ) | | (246 | ) |
Amounts reclassified from accumulated other comprehensive income | — |
| | — |
| | — |
|
Net current period other comprehensive loss | (12 | ) | | (234 | ) | | (246 | ) |
Balance at September 30, 2016 | $ | (2,854 | ) | | $ | (186 | ) | | $ | (3,040 | ) |
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
17.18. Restructuring Costs
During 2015, management evaluated several initiatives to improve the overall operating efficiency of the organization. As a result of this evaluation, wethe Company launched an initiative to reduce ourits cost structure by implementing various staff reduction actions during the third quarter of 2015.
In addition, during the fourth quarter of 2015, the Company experienced a management transition of certain high-level positions, most notably the Chief Executive Officer and the Chief Financial Officer.
The following table summarizes the fiscal year 20172018 activities related to these restructuring initiatives for severance and benefits:
|
| | | |
For the three months ended September 30, 2017 | Restructuring Costs |
Balance at June 30, 2017 | $ | 3,136 |
|
Expense recorded | — |
|
Payments made | (761 | ) |
Balance at September 30, 2017 | $ | 2,375 |
|
| |
For the nine months ended September 30, 2017 | Restructuring Costs |
Balance at December 31, 2016 | $ | 6,356 |
|
Expense recorded | — |
|
Payments made | (3,981 | ) |
Balance at September 30, 2017 | $ | 2,375 |
|
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
|
| | | |
For the three months ended March 31, 2018 | Restructuring Costs |
Balance at December 31, 2017 | $ | 1,929 |
|
Expense recorded | — |
|
Payments made | (1,676 | ) |
Balance at March 31, 2018 | $ | 253 |
|
| |
18.19. Segment Reporting
The Company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and EBITDA (defined as net income (loss) before interest, income taxes, depreciation and amortization). All references to sales in this Quarterly Report on Form 10-Q are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.
The Company's chief executive officer is the chief operating decision maker and as of the first quarter of 2017, has determined to assess the Company's performance and allocate the appropriate resources based on the following operating segments: (1) Food, Health and Nutrition,Nutrition; (2) Industrial SpecialtiesSpecialties; and (3) Other. The newThese reporting segments accurately reflect the underlying business dynamics and align with the strategic direction of the Company. Prior to the first quarter of 2017, the reporting segments were (1) Specialty Phosphates US & Canada, (2) Specialty Phosphates Mexico and (3) Granular Triple Super Phosphate, or GTSP & Other, versus the current market view.
| | For the three months ended September 30, 2017 | | Food, Health and Nutrition | | Industrial Specialties | | Other | | Total | |
For the three months ended March 31, 2018 | | | Food, Health and Nutrition | | Industrial Specialties | | Other | | Total |
Sales | | $ | 98,276 |
|
| $ | 67,682 |
|
| $ | 17,881 |
|
| $ | 183,839 |
| | $ | 126,363 |
|
| $ | 63,350 |
|
| $ | 15,727 |
|
| $ | 205,440 |
|
EBITDA | | $ | 16,442 |
|
| $ | 13,491 |
|
| $ | (1,145 | ) |
| $ | 28,788 |
| | $ | 18,992 |
|
| $ | 10,093 |
|
| $ | 786 |
|
| $ | 29,871 |
|
Depreciation and amortization expense | | $ | 5,664 |
|
| $ | 3,488 |
|
| $ | 726 |
|
| $ | 9,878 |
| | $ | 7,322 |
|
| $ | 3,736 |
|
| $ | 306 |
|
| $ | 11,364 |
|
| | | | | | | | | | | | | | | | |
For the three months ended September 30, 2016 | | Food, Health and Nutrition | | Industrial Specialties | | Other | | Total | |
For the three months ended March 31, 2017 | | | Food, Health and Nutrition | | Industrial Specialties | | Other | | Total |
Sales | | $ | 93,586 |
| | $ | 70,124 |
| | $ | 22,327 |
| | $ | 186,037 |
| | $ | 91,083 |
| | $ | 63,672 |
| | $ | 11,189 |
| | $ | 165,944 |
|
EBITDA | | $ | 19,649 |
| | $ | 10,237 |
| | $ | 1,942 |
| | $ | 31,828 |
| | $ | 15,624 |
| | $ | 9,521 |
| | $ | 898 |
| | $ | 26,043 |
|
Depreciation and amortization expense | | $ | 5,802 |
| | $ | 2,957 |
| | $ | 1,284 |
| | $ | 10,043 |
| | $ | 5,722 |
| | $ | 3,372 |
| | $ | 487 |
| | $ | 9,581 |
|
| | | | | | | | | | | | | | | | |
For the nine months ended September 30, 2017 | | Food, Health and Nutrition | | Industrial Specialties | | Other | | Total | |
Sales | | $ | 281,558 |
| | $ | 198,721 |
| | $ | 48,644 |
| | $ | 528,923 |
| |
EBITDA | | $ | 49,098 |
| | $ | 31,666 |
| | $ | 2,086 |
| | $ | 82,850 |
| |
Depreciation and amortization expense | | $ | 16,884 |
| | $ | 10,346 |
| | $ | 1,779 |
| | $ | 29,009 |
| |
| | | | | | | | | |
For the nine months ended September 30, 2016 | | Food, Health and Nutrition | | Industrial Specialties | | Other | | Total | |
Sales | | $ | 286,660 |
| | $ | 216,591 |
| | $ | 54,304 |
| | $ | 557,555 |
| |
EBITDA | | $ | 59,326 |
| | $ | 29,934 |
| | $ | 1,698 |
| | $ | 90,958 |
| |
Depreciation and amortization expense | | $ | 15,845 |
| | $ | 9,554 |
| | $ | 3,208 |
| | $ | 28,607 |
| |
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
A reconciliation of net income to EBITDA follows:
| | | | Three months ended | | Three months ended |
| | September 30, 2017 | | September 30, 2016 | | March 31, 2018 | | March 31, 2017 |
Net income | | $ | 11,582 |
| | $ | 13,643 |
| | $ | 10,915 |
| | $ | 10,923 |
|
Provision for income taxes | | 5,698 |
| | 6,227 |
| | 4,688 |
| | 4,186 |
|
Interest expense, net | | 1,630 |
| | 1,915 |
| | 2,904 |
| | 1,353 |
|
Depreciation and amortization | | 9,878 |
| | 10,043 |
| | 11,364 |
| | 9,581 |
|
EBITDA | | $ | 28,788 |
| | $ | 31,828 |
| | $ | 29,871 |
| | $ | 26,043 |
|
| | | | | | | | |
| | Nine months ended | |
| | September 30, 2017 | | September 30, 2016 | |
Net income | | $ | 33,728 |
| | $ | 38,589 |
| |
Provision for income taxes | | 15,678 |
| | 18,135 |
| |
Interest expense, net | | 4,435 |
| | 5,627 |
| |
Depreciation and amortization | | 29,009 |
| | 28,607 |
| |
EBITDA | | $ | 82,850 |
| | $ | 90,958 |
| |
|
| | | | | | | | | | | | | | | | |
Total assets by segment | | Food, Health and Nutrition | | Industrial Specialties | | Other | | Total |
For the period ended September 30, 2017 (a) | | $ | 534,641 |
| | $ | 203,633 |
| | $ | 32,492 |
| | $ | 770,766 |
|
For the period ended September 30, 2016 | | 397,575 |
| | 210,680 |
| | 34,756 |
| | 643,011 |
|
(a) Food, Health and Nutrition increased by $148.2 million with the acquisition of Novel Ingredients.
| |
ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Innophos is a leading international producer of specialty ingredient solutions that deliver versatile benefits for the food, health, nutrition and industrial markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a broad range of other specialty nutritional ingredients. Many of Innophos' products are application-specific compounds engineered to meet customer performance requirements and are often critical to the taste, texture and performance of foods, beverages, pharmaceuticals, oral care products and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods, pharmaceutical excipients, cleaning agents in toothpaste, and they also provide a wide range of nutritional fortification solutions for food, beverage and nutritional supplement manufacturers.
Full Year 2017Recent Trends and Outlook
The proactive selling price increase program that was implemented in the fourth quarter of 2017 fiscalhas been effective in offsetting input cost increases in the first quarter. In response to the operating environment continuing to show cost inflation, the Company has taken further price increase actions in its specialty phosphates portfolio to take effect on June 1, 2018.
The Company continues to expect full year includes2018 revenue to grow 12% to 14% due to the annualized contributions from Novel Ingredientsacquisitions, favorable growth in both Q3the specialty nutrition end-markets served, and Q4 with estimated sales of $35 million.stabilization in the legacy business.
Q4Full year GAAP EPS is expected to reflect typical seasonality withmore than double in 2018. This includes an improvement in 2018 full year EPS of approximately $0.16 per diluted share due to the lower sequential sales and unfavorable mix.
Demand impact from the recent natural disasters is expected to carry into Q4 and forecasted to have an unfavorable $3 million effect on sales for the full year.
An estimated $3 million of Phase 2 Operational Excellence savings will take effect in 2017, $2 million of which will be recorded in Q4.Near term logistics savings are being impacted by lack of trucking equipment availability following recent hurricanes.effective tax rate.
The Company is planning aexpects free cash flow (net cash provided from operating activities plus cash used for capital expenditures) to be similar to prior year with capital cash outflow of approximately $45 million to principally support the strategic value chain repositioning and manufacturing stoppage in Q4 as a first step in a broader plant maintenance and supply chain optimization program that will be phased throughout 2018, demonstrating our continued commitment to our phosphates product portfolio. This stoppage will impact earnings adversely by approximately $4 million due to maintenance expense, lower fixed costs absorption and higher cost of externally sourced material.programs.
Results of Operations
The following table sets forth a summary of the Company’s operations and their percentages of total revenue for the periods indicated (dollars in millions):
| | | Three Months Ended | | Three Months Ended | Three Months Ended | | Three Months Ended |
| September 30, 2017 | | September 30, 2016 | March 31, 2018 | | March 31, 2017 |
| Amount | | % | | Amount | | % | Amount | | % | | Amount | | % |
Net sales | $ | 183.8 |
| | 100.0 |
| | $ | 186.0 |
| | 100.0 |
| $ | 205.4 |
| | 100.0 |
| | $ | 165.9 |
| | 100.0 |
|
Cost of goods sold | 142.8 |
| | 77.7 |
| | 145.5 |
| | 78.2 |
| 163.2 |
| | 79.5 |
| | 129.4 |
| | 78.0 |
|
Gross profit | 41.0 |
| | 22.3 |
| | 40.5 |
| | 21.8 |
| 42.2 |
| | 20.5 |
| | 36.5 |
| | 22.0 |
|
Operating expenses: | | | | | | | | | | | | | | |
Selling, general and administrative | 20.9 |
| | 11.4 |
| | 17.7 |
| | 9.5 |
| 22.5 |
| | 11.0 |
| | 19.3 |
| | 11.6 |
|
Research & development | 1.1 |
| | 0.6 |
| | 0.9 |
| | 0.5 |
| 1.4 |
| | 0.7 |
| | 0.8 |
| | 0.5 |
|
Income from operations | 19.0 |
| | 10.3 |
| | 21.9 |
| | 11.8 |
| 18.3 |
| | 8.9 |
| | 16.4 |
| | 9.9 |
|
Interest expense, net | 1.6 |
| | 0.9 |
| | 1.9 |
| | 1.0 |
| 2.9 |
| | 1.4 |
| | 1.4 |
| | 0.8 |
|
Foreign exchange loss, net | 0.1 |
| | 0.1 |
| | 0.1 |
| | 0.1 |
| |
Foreign exchange gain, net | | (0.2 | ) | | (0.1 | ) | | (0.1 | ) | | (0.1 | ) |
Provision for income taxes | 5.7 |
| | 3.1 |
| | 6.3 |
| | 3.4 |
| 4.7 |
| | 2.3 |
| | 4.2 |
| | 2.5 |
|
Net income | $ | 11.6 |
| | 6.3 |
| | $ | 13.6 |
| | 7.3 |
| $ | 10.9 |
| | 5.3 |
| | $ | 10.9 |
| | 6.6 |
|
| | | | | | | | | | | | | | |
| Nine Months Ended | | Nine Months Ended | |
| September 30, 2017 | | September 30, 2016 | |
| Amount | | % | | Amount | | % | |
Net sales | $ | 528.9 |
| | 100.0 |
| | $ | 557.5 |
| | 100.0 |
| |
Cost of goods sold | 412.3 |
| | 78.0 |
| | 440.1 |
| | 78.9 |
| |
Gross profit | 116.6 |
| | 22.0 |
| | 117.4 |
| | 21.1 |
| |
Operating expenses: | | | | | | | | |
Selling, general and administrative | 60.1 |
| | 11.4 |
| | 51.7 |
| | 9.3 |
| |
Research & development | 2.7 |
| | 0.5 |
| | 2.9 |
| | 0.5 |
| |
Income from operations | 53.8 |
| | 10.2 |
| | 62.8 |
| | 11.3 |
| |
Interest expense, net | 4.4 |
| | 0.8 |
| | 5.6 |
| | 1.0 |
| |
Foreign exchange loss, net | — |
| | — |
| | 0.5 |
| | 0.1 |
| |
Provision for income taxes | 15.7 |
| | 3.0 |
| | 18.1 |
| | 3.3 |
| |
Net income | 33.7 |
| | 6.4 |
| | 38.6 |
| | 6.9 |
| |
Three months ended September 30, 2017March 31, 2018 compared to the three months ended September 30, 2016March 31, 2017
Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the three months ended September 30, 2017March 31, 2018 were $183.8$205.4 million, a decreasean increase of $2.2$39.5 million, or 1.2%23.8%, as compared to $186.0$165.9 million for the same period in 2016,2017, with prices down 4.5%up 1.5%, partially offsetand volumes higher by higher volumes22.3%, of 3.3%.which 20.2% resulted from acquisitions made in the second half of 2017 and 2.1% resulted from the legacy business. Food, Health and Nutrition (FHN) segment sales were up 5.0%38.7%, or $4.7$35.3 million, with selling prices lowerhigher by 3.4%0.5%, or $3.2$0.5 million, principally inand volumes higher by 38.2%, or $34.8 million. The 2017 acquisitions contributed $33.6 million, or 36.9%, of the Food business which was driven by unfavorable market conditions,volume growth and the overall Food, Health and Nutrition segment was adversely affectedlegacy business grew by customer mix. The Food, Health and Nutrition segment had positive volume results in the current quarter with 5 weeks of sales totaling $10.2$1.2 million, from the newly acquired Novel Ingredients business.or 1.3%. Industrial Specialties sales were down 3.5%0.5%, or $2.4$0.3 million, with volumes lower by 3.0%, or $1.9 million, but selling prices lowerhigher by 4.8%2.5%, or $3.4 million, due to price competition in technical-grade phosphates, partially offset by higher volumes of 1.3%, or $1.0$1.6 million. Other sales were lowerhigher by 19.9%40.6%, or $4.5 million, with volume lowerhigher by 12.0%37.4%, or $2.7$4.1 million, due to strong commodityadditional sales to South American fertilizer sales in the prior year period,markets, and selling prices lowerhigher by 7.9%3.2%, or $1.8$0.4 million.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.
The following table illustrates for the three months ended September 30, 2017March 31, 2018 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
| | | Price | | Volume/Mix | | Total | Price | | Volume/Mix | | Total |
Food, Health and Nutrition | (3.4 | )% | | 8.4 | % | | 5.0 | % | 0.5 | % | | 38.2 | % | | 38.7 | % |
Industrial Specialties | (4.8 | )% | | 1.3 | % | | (3.5 | )% | 2.5 | % | | (3.0 | )% | | (0.5 | )% |
Other | (7.9 | )% | | (12.0 | )% | | (19.9 | )% | 3.2 | % | | 37.4 | % | | 40.6 | % |
Total | (4.5 | )% | | 3.3 | % | | (1.2 | )% | 1.5 | % | | 22.3 | % | | 23.8 | % |
Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the three months ended September 30, 2017March 31, 2018 was $41.0$42.2 million, an increase of $0.5$5.7 million, or 1.2%15.6%, as compared to $40.5$36.5 million for the same period in 2016.2017. Gross profit as a percentage of net sales increaseddecreased to 22.3%20.5% for the three months ended September 30, 2017March 31, 2018 versus 21.8%22.0% for the same period in 2016 due to improving mix into higher value products.2017. Gross profit in 20172018 was favorably affected by $7.7$10.8 million lowerfrom higher sales volumes, including sales volumes from the 2017 acquisition companies, and $2.5 million higher selling prices. Gross profit was unfavorably affected in 2018 by $3.6 million of higher manufacturing costs, $2.3 million of higher raw material costs, mainly phosphate rocksulfur, and MGA, $0.6$1.7 million lowerhigher depreciation and $0.3 million lower manufacturing costs. These favorable effects were partially offset by $8.4 million lower selling prices, $0.4 million unfavorable exchange rates from our Mexican peso and Canadian dollar based costs, and $0.1 million lower sales volumes. Results from the newly acquired Novel Ingredients business favorably affected gross profit by $0.8 million, which includes a $1.4 million charge for fair value inventory purchase accounting.intangible amortization expense.
Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the three months ended September 30, 2017March 31, 2018 were $22.0$23.9 million, an increase of $3.4$3.8 million, or 18.3%18.9%, as compared to $18.6$20.1 million for the same period in 2016.2017. The increase was mainly due to $3.0 million of transaction and integration costs related toacquisitions included in the Novel Ingredients acquisition and $1.7 million of Novel Ingredients operating expenses for the period, partially offset by $1.3 million lower employee related costs.current year cost base.
Operating Income
Operating income for the three months ended September 30, 2017March 31, 2018 was $19.0$18.3 million, a decreasean increase of $2.9$1.9 million, or 13.2%11.6%, as compared to $21.9$16.4 million for the same period in 2016.2017. Operating income as a percentage of net sales decreased to 10.3%8.9% versus 11.8%9.9% for the same period in 2016,2017, for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the three months ended September 30, 2017March 31, 2018 was $1.62.9 million, a decreasean increase of $0.3$1.5 million, or 15.8%107.1%, as compared to $1.91.4 million for the same period in 2016.2017. The decreaseincrease was primarily due to lowerhigher market interest rates under our December 2016 renewed credit facility.and a higher average loan balance due from the 2017 acquisitions.
Foreign Exchange
Foreign exchange for the three months ended September 30, 2017March 31, 2018 was a gain of $0.1$0.2 million as compared to a gain of $0.1 million for the same period in 2016.2017. The US Dollar is the functional currency of our Mexican and Canadian operations. The Company has greater foreign denominated asset balances (largely Mexican Peso and Canadian Dollar), such as VAT receivables and prepaid income taxes in foreign jurisdictions, than offsetting foreign denominated liability balances. Foreign exchange gain or loss is recorded on remeasurement of non-US Dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the US Dollar and the amount of non-US Dollar denominated assets and liabilities increases or decreases.
Provision for Income Taxes
The effective income tax rate on income before taxes was 33%approximately 30% for the three months ended September 30, 2017March 31, 2018 compared to 31%approximately 28% for the samecomparable period in 2016. The variances in the effective tax rate are primarily due to prior year tax return true-ups which increased the effective tax rate by 3% as compared to the same period last year, partially offset by increased income in lower tax rate jurisdictions which decreased the effective tax rate by 1% in the current quarter.
Net Income
Net income for the three months ended September 30, 2017 was $11.6 million, a decrease of $2.0 million, as compared to $13.6 million for the same period in 2016, due to the factors described above.
Nine months ended September 30, 2017 compared to the nine months ended September 30, 2016
Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the nine months ended September 30, 2017 were $528.9 million, a decrease of $28.6 million, or 5.1%, as compared to $557.5 million for the same period in 2016, with prices down 5.0% and volumes down 0.1%. Food, Health and Nutrition sales were down 1.8%, or $5.1 million, with selling prices lower by 3.6%, or $10.4 million, principally driven by unfavorable market conditions and customer mix. The Food, Health and Nutrition volume results were higher by 1.8%, or $5.3 million, largely driven by $10.2 million from the results of the newly acquired Novel Ingredients business. Industrial Specialties sales were down 8.3%, or $17.9 million, with selling prices lower by 6.1%, or $13.3 million, due to price competition in technical-grade phosphates, and volumes lower by 2.2%, or $4.6 million. Other sales were lower by 10.4%, or $5.6 million, with prices lower by 7.3%, or $3.9 million, and volumes lower by 3.1%, or $1.7 million.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.
The following table illustrates for the nine months ended September 30, 2017 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
|
| | | | | | | | |
| Price | | Volume/Mix | | Total |
Food, Health and Nutrition | (3.6 | )% | | 1.8 | % | | (1.8 | )% |
Industrial Specialties | (6.1 | )% | | (2.2 | )% | | (8.3 | )% |
Other | (7.3 | )% | | (3.1 | )% | | (10.4 | )% |
Total | (5.0 | )% | | (0.1 | )% | | (5.1 | )% |
Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the nine months ended September 30, 2017 was $116.6 million, a decrease of $0.8 million, or 0.7%, as compared to $117.4 million for the same period in 2016. Gross profit percentage of net sales increased to 22.0% for the nine months ended September 30, 2017 versus 21.1% for the same period in 2016 due to improving mix into higher value products. Gross profit in 2017 was favorably affected by $28.7 million lower raw material costs, mainly phosphate rock and MGA, and $2.6 million lower manufacturing costs. These favorable effects were partially offset by $27.6 million lower selling prices, $5.4 million lower sales volumes, and $3.2 million expenses for the implementation of Phase 2 Operational Excellence initiatives. Results from the newly acquired Novel Ingredients business favorably affected gross profit by $0.8 million, which includes a charge of $1.4 million for fair value inventory purchase accounting. Included in 2016 gross profit was $2.4 million planned maintenance outage expense at our Coatzacoalcos, Mexico manufacturing facility and a $0.9 million charge for a GTSP lower of cost or market reserve.
Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative expenses and research and development expenses. Operating expenses for the nine months ended September 30, 2017 were $62.8 million, an increase of $8.2 million, or 15.0%, as compared to $54.6 million for the same period in 2016. The increase was due to $3.3 million for strategic initiatives, $3.0 million of transaction and integration costs related to the Novel Ingredients acquisition, $1.7 million of Novel Ingredients operating expenses for the current period, $1.1 million higher severance costs, partially offset by $0.9 million lower employee related expenses.
Operating Income
Operating income for the nine months ended September 30, 2017 was $53.8 million, a decrease of $9.0 million, or 14.3%, as compared to $62.8 million for the same period in 2016. Operating income as a percentage of net sales decreased to 10.2% versus 11.3% for the same period in 2016 for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the nine months ended September 30, 2017 was $4.4 million, a decrease of $1.2 million, or 21.4%, as compared to $5.6 million for the same period in 2016. The decrease was primarily due to lower average loan balances and interest rates, lower leverage ratios and lower applicable margins under our December 2016 renewed credit facility.
Foreign Exchange
Foreign exchange for the nine months ended September 30, 2017 was zero compared to a gain of $0.5 million for the same period in 2016. The US Dollar is the functional currency of our Mexican and Canadian operations. The Company has greater foreign denominated asset balances (largely Mexican Peso and Canadian Dollar), such as VAT receivables and prepaid income taxes in foreign jurisdictions, than offsetting foreign denominated liability balances. Foreign exchange gain or loss is recorded on remeasurement of non-US Dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the US Dollar and the amount of non-US Dollar denominated assets and liabilities increases or decreases.
Provision for Income Taxes
The effective income tax rate was 32% for the nine months ended September 30, 2017 compared to 32% for the same period in 2016.2017. The change in the components of the effective tax rate are primarily due to the adoptionenactment of ASU No. 2016-09, Improvementsthe U.S. Tax Cuts and Jobs Act and changes in excess tax benefit from stock-based compensation. The reduction in the statutory U.S. Federal corporate tax rate and a change of mix of U.S. to Employee Share-Based Payment Accounting, changingforeign earnings resulted in an 8% decrease in the accounting foreffective tax benefits from stock option exercises and vesting of restricted stock and performance awards, which decreasedrate. This was offset by the incremental U.S. tax on global intangible low-taxed income resulting in an increase to the effective tax rate by 2%,4%. Further, the rate increased 5% resulting from a permanent adjustment attributable to an inventory obsolescence reserve in Mexico in the prior year, which decreased the effectivesmaller excess tax rate by 1% as compared to last year and prior year tax return true-ups which increased the effective tax rate by 3% as compared to last year.benefit from stock-based compensation.
Net Income
Net income for the ninethree months ended September 30, 2017March 31, 2018 was $33.7 million, a decrease of $4.9$10.9 million, as compared to $38.6$10.9 million for the same period in 2016,2017, due to the factors described above.
Segment Reporting
The Company's chief executive officer is the chief operating decision maker and as of the first quarter of 2017, has determined to assess the Company's performance and allocate the appropriate resources based on the following operating segments: (1) Food, Health and Nutrition,Nutrition; (2) Industrial SpecialtiesSpecialties; and (3) Other. The new reporting segments accurately reflect the underlying business dynamics and align with the strategic direction of the Company. The primary performance indicators for the chief operating decision maker are sales and earnings before interest, taxes, depreciation and amortization, or EBITDA. The following table sets forth the results of these indicators by segment for the three and nine months ended September 30, 2017March 31, 2018 and 2016:2017:
| |
| Three Months Ended |
|
| Three Months Ended |
|
|
| September 30, 2017 |
| September 30, 2016 |
| Net Sales % Change | March 31, 2018 |
| March 31, 2017 |
| Net Sales % Change |
Segment Net Sales |
|
|
|
|
|
|
|
|
|
|
Food, Health and Nutrition | $ | 98,276 |
|
| $ | 93,586 |
|
| 5.0 | % | $ | 126,363 |
|
| $ | 91,083 |
|
| 38.7 | % |
Industrial Specialties | 67,682 |
|
| 70,124 |
|
| (3.5 | )% | 63,350 |
|
| 63,672 |
|
| (0.5 | )% |
Other | 17,881 |
|
| 22,327 |
|
| (19.9 | )% | 15,727 |
|
| 11,189 |
|
| 40.6 | % |
Total | $ | 183,839 |
|
| $ | 186,037 |
|
| (1.2 | )% | $ | 205,440 |
|
| $ | 165,944 |
|
| 23.8 | % |
| Segment EBITDA |
|
|
|
|
|
|
|
|
|
|
Food, Health and Nutrition | $ | 16,442 |
|
| $ | 19,649 |
|
|
|
| $ | 18,992 |
|
| $ | 15,624 |
|
|
|
|
Industrial Specialties | 13,491 |
|
| 10,237 |
|
|
|
| 10,093 |
|
| 9,521 |
|
|
|
|
Other | (1,145 | ) |
| 1,942 |
|
|
|
| 786 |
|
| 898 |
|
|
|
|
Total | $ | 28,788 |
|
| $ | 31,828 |
|
|
|
| $ | 29,871 |
|
| $ | 26,043 |
|
|
|
|
| Segment EBITDA % of net sales |
|
|
|
|
|
|
|
|
|
|
Food, Health and Nutrition | 16.7 | % |
| 21.0 | % |
|
|
| 15.0 | % |
| 17.2 | % |
|
|
|
Industrial Specialties | 19.9 | % |
| 14.6 | % |
|
|
| 15.9 | % |
| 15.0 | % |
|
|
|
Other | (6.4 | )% |
| 8.7 | % |
|
|
| 5.0 | % |
| 8.0 | % |
|
|
|
Total | 15.7 | % |
| 17.1 | % |
|
|
| 14.5 | % |
| 15.7 | % |
|
|
|
| Depreciation and amortization expense |
|
|
|
|
|
|
|
|
|
|
Food, Health and Nutrition | $ | 5,664 |
|
| $ | 5,802 |
|
|
|
| $ | 7,322 |
|
| $ | 5,722 |
|
|
|
|
Industrial Specialties | 3,488 |
|
| 2,957 |
|
|
|
| 3,736 |
|
| 3,372 |
|
|
|
|
Other | 726 |
|
| 1,284 |
|
|
|
| 306 |
|
| 487 |
|
|
|
|
Total | $ | 9,878 |
|
| $ | 10,043 |
|
|
|
| $ | 11,364 |
|
| $ | 9,581 |
|
|
|
|
|
| | | | | | | | | | |
| Nine Months Ended | | |
| September 30, 2017 | | September 30, 2016 | | Net Sales % Change |
Segment Net Sales | | | | | |
Food, Health and Nutrition | $ | 281,558 |
| | $ | 286,660 |
| | (1.8 | )% |
Industrial Specialties | 198,721 |
| | 216,591 |
| | (8.3 | )% |
Other | 48,644 |
| | 54,304 |
| | (10.4 | )% |
Total | $ | 528,923 |
| | $ | 557,555 |
| | (5.1 | )% |
| | | | | |
Segment EBITDA | | | | | |
Food, Health and Nutrition | $ | 49,098 |
| | $ | 59,326 |
| | |
Industrial Specialties | 31,666 |
| | 29,934 |
| | |
Other | 2,086 |
| | 1,698 |
| | |
Total | $ | 82,850 |
| | $ | 90,958 |
| | |
| | | | | |
Segment EBITDA % of net sales | | | | | |
Food, Health and Nutrition | 17.4 | % | | 20.7 | % | | |
Industrial Specialties | 15.9 | % | | 13.8 | % | | |
Other | 4.3 | % | | 3.1 | % | | |
Total | 15.7 | % | | 16.3 | % | | |
| | | | | |
Depreciation and amortization expense | | | | | |
Food, Health and Nutrition | $ | 16,884 |
| | $ | 15,845 |
| | |
Industrial Specialties | 10,346 |
| | 9,554 |
| | |
Other | 1,779 |
| | 3,208 |
| | |
Total | $ | 29,009 |
| | $ | 28,607 |
| | |
A reconciliation of net income to EBITDA follows:
| |
|
| Three months ended |
| Three months ended |
|
| September 30, 2017 |
| September 30, 2016 |
| March 31, 2018 |
| March 31, 2017 |
Net income |
| $ | 11,582 |
|
| $ | 13,643 |
|
| $ | 10,915 |
|
| $ | 10,923 |
|
Provision for income taxes |
| 5,698 |
|
| 6,227 |
|
| 4,688 |
|
| 4,186 |
|
Interest expense, net |
| 1,630 |
|
| 1,915 |
|
| 2,904 |
|
| 1,353 |
|
Depreciation and amortization |
| 9,878 |
|
| 10,043 |
|
| 11,364 |
|
| 9,581 |
|
EBITDA |
| $ | 28,788 |
|
| $ | 31,828 |
|
| $ | 29,871 |
|
| $ | 26,043 |
|
|
| | | | | | | | |
| | Nine months ended |
| | September 30, 2017 | | September 30, 2016 |
Net income | | $ | 33,728 |
| | $ | 38,589 |
|
Provision for income taxes | | 15,678 |
| | 18,135 |
|
Interest expense, net | | 4,435 |
| | 5,627 |
|
Depreciation and amortization | | 29,009 |
| | 28,607 |
|
EBITDA | | $ | 82,850 |
| | $ | 90,958 |
|
Three months ended September 30, 2017March 31, 2018 compared to the three months ended September 30, 2016March 31, 2017
Segment Net Sales:
Food, Health and Nutrition net sales increased 5.0%38.7% for the three months ended September 30, 2017March 31, 2018 compared with the same period in 2016.2017. Volumes increased 8.4%, partially offset by an38.2% and average selling price decrease ofincreased 3.4%0.5%. The Food, Health and Nutrition net sales were favorably affected 11.0%increased by 36.9% due to the inclusion of the results of the newly acquired Novel Ingredients business. Lower selling prices were primarily due to unfavorable market/customer mix.2017 acquisitions.
Industrial Specialties net sales decreased 3.5%0.5% for the three months ended September 30, 2017March 31, 2018 compared with the same period in 2016. Average selling prices2017. Volumes decreased 4.8%3.0%, primarily due to strong competition in technical grade products, partially offset by increased volumes of 1.3%.a 2.5% increase in average selling prices.
Other net sales decreasedincreased 19.9%40.6% for the three months ended September 30, 2017March 31, 2018 compared with the same period in 2016.2017. Volumes decreased 12.0%, mostly due to strong commodity fertilizer sales in the prior year period,increased 37.4% and average selling prices decreased 7.9%increased 3.2%.
Segment EBITDA Percentage of Net Sales:
The 430220 basis point decrease in Food, Health and Nutrition EBITDA margins for the three months ended September 30, 2017March 31, 2018 compared with the same period in 20162017 is due to lower average selling pricesthe 2017 acquisitions which decreased margins by 280230 basis points, increased raw material costs, mainly sulfur, which decreased margins by 150 basis points, lower sales volume/mix which decreased margins by 180 basis points, the inclusion of the newly acquired Novel Ingredients business which decreased margins by 240 basis points, primarily due to a fair value inventory adjustment which decreased margins by 15020 basis points, and other higher operating costs which decreased margins by 7020 basis points. This decrease was partially offset by lower manufacturing costs which increased margins by 220150 basis points, and decreased raw material costs, mainly phosphate rock and MGA,higher average selling prices which increased margins by 12040 basis points, and the change in translation which increased margins by 10 basis points.
The 53090 basis point increase in Industrial Specialties EBITDA margins for the three months ended September 30, 2017March 31, 2018 compared with the same period in 20162017 is due to lower raw material costs, mainly phosphate rock and MGA,higher average selling prices which increased margins by 470210 basis points, higher sales volume/mix which increased margins by 310160 basis points, and lower manufacturing and operating costs which increased margins by 28070 basis points. This increase was partially offset by lower average selling priceshigher manufacturing costs which decreased margins 200 basis points and higher raw material costs, mainly sulfur, which decreased margins by 440 basis points, and other higher costs which decreased margins by 90150 basis points.
The 1,510300 basis point decrease in Other EBITDA margins for the three months ended September 30, 2017March 31, 2018 compared with the same period in 20162017 is due to higher manufacturing and operating costs which decreased margins 1,570 basis points, higher strategic project expenses which decreased margins by 1,340 basis points, and lower selling prices which decreased margins 8002,020 basis points. This decrease was partially offset by higher sales volume/mix which increased margins by 1,010 basis points, lower operating costs which increased margins 330 basis points, higher selling prices which increased margins 290 basis points, the change in translation which increased margins by 50 basis points, and lower raw material costs which increased margins by 1,480 basis points and higher sales volume/mix which increased margins by 720 basis points.
Nine months ended September 30, 2017 compared to the nine months ended September 30, 2016
Segment Net Sales:
Food, Health and Nutrition net sales decreased 1.8% for the nine months ended September 30, 2017 compared with the same period in 2016. Average selling prices decreased by 3.6%, primarily due to unfavorable market/customer mix, which was partially offset by increased volumes of 1.8%. The Food, Health and Nutrition net sales were favorably affected 3.6% from the results of the newly acquired Novel Ingredients business.
Industrial Specialties net sales decreased 8.3% for the nine months ended September 30, 2017 compared with the same period in 2016. Average selling prices decreased 6.1%, due to competitive pressures on technical grade products, and volumes decreased 2.2%, primarily due to the year-over-year effect from pruning of lower margin, less differentiated applications.
Other net sales decreased 10.4% for the nine months ended September 30, 2017 compared with the same period in 2016. Average selling prices decreased 7.3%, due to lower commodity market prices, and volumes decreased 3.1%.
Segment EBITDA Percentage of Net Sales:
The 330 basis point decrease in Food, Health and Nutrition EBITDA margins for the nine months ended September 30, 2017 compared with the same period in 2016 is due to lower average selling prices which decreased margins by 300 basis points, higher strategic project expenses which decreased margins by 130 basis points, lower sales volume/mix which decreased margins by 130 basis points and the inclusion of the newly acquired Novel Ingredients business which decreased margins by 80 basis points, primarily due to a fair value inventory adjustment which decreased margins by 50 basis points. This decrease was partially offset by decreased raw material costs, mainly phosphate rock and MGA, which increased margins by 220 basis points and lower manufacturing and operating costs which increased margins by 70 basis points. Included in 2016 was turnaround costs which increased margins by 20 basis points in 2017.
The 210 basis point increase in Industrial Specialties EBITDA margins for the nine months ended September 30, 2017 compared with the same period in 2016 is due to lower raw material costs, mainly phosphate rock and MGA, which increased margins by 550 basis points, lower manufacturing and operating cost which increased margins by 200 basis points, and higher sales volume/mix which increased margins by 130 basis points. This increase was partially offset by lower average selling prices which decreased margins by 560 basis points, higher strategic project expenses which decreased margins by 130 basis points, and increased severance cost which decreased margins by 30 basis points. Included in 2016 was turnaround costs which increased margins by 50 basis points in 2017.
The 120 basis point increase in Other EBITDA margins for the nine months ended September 30, 2017 compared with the same period in 2016 is due to lower raw material costs which increased margins by 1,860 basis points, higher sales volume/mix which increased margins by 170 basis points, and favorable translation effects which increased margins by 40 basis points. This increase was partially offset by higher manufacturing and operating costs which decreased margins by 890 basis points, lower selling prices which decreased margins by 770 basis points, and higher strategic project expenses which decreased margins by 570 basis points. Included in 2016 was a $0.9 million charge for a GTSP lower of cost or market reserve which increased margins by 170 basis points in 2017, and turnaround costs which increased margins by 110 basis points in 2017.
Liquidity and Capital Resources
Cash Flow Summary
The following table sets forth a summary of the Company’s cash flows for the periods indicated.
| | (Dollars in millions) | Six months ended | Three months ended |
| September 30, 2017 | | September 30, 2016 | March 31, 2018 | | March 31, 2017 |
Operating Activities | $ | 46.7 |
| | $ | 81.8 |
| $ | (4.2 | ) | | $ | (10.7 | ) |
Investing Activities | (148.6 | ) | | (25.7 | ) | (9.4 | ) | | (7.5 | ) |
Financing Activities | 81.2 |
| | (41.6 | ) | 25.4 |
| | (5.7 | ) |
Effect of foreign exchange rate changes | — |
| | 0.3 |
| 0.2 |
| | 0.2 |
|
NineThree months ended September 30, 2017March 31, 2018 compared to ninethree months ended September 30, 2016March 31, 2017
Net cash fromused by operating activities was $46.7$4.2 million for the ninethree months ended September 30, 2017 asMarch 31, 2018 compared to $81.8a use of $10.7 million for 2016, a decrease2017, an increase in cash of $35.1$6.5 million. The decreaseincrease in operating activities cash resulted from unfavorablefavorable changes of $32.3$3.2 million in working capital, $2.2 million non-cash adjustments to income and $4.9 million in net income, as described above, partially offset bya favorable changeschange of $1.7$1.1 million in other long term assets and liabilities and $0.4 million non-cash adjustments to income.liabilities.
The change in working capital is derived from it being a use of cash of $15.9$26.8 million in 2018 compared to a use of $30.0 million in 2017, compared to a source of $16.4 million in 2016, a decreasean increase in cash of $32.3$3.2 million. The change in working capital was due to unfavorablefavorable changes in inventory of $30.2 million, driven by adjusting inventory levels in the prior year, accounts receivable of $12.9 million due to the effects of extended payment terms, other current assets of $2.0$4.5 million, primarily due to timing of vendor prepayments, accounts receivable of $0.9 million, and accounts payableinventory of $5.0$0.4 million. Accounts receivable has increased as a percent of quarterly sales compared to the last four quarters' average due to pressures on customer payment terms. These unfavorablefavorable effects were partially offset by a favorable changeunfavorable changes in other current liabilities of $17.8$2.0 million largely due to U.S. income tax payments in the prior year.and accounts payable of $0.6 million.
Net cash used for investing activities was $148.6$9.4 million for the ninethree months ended September 30, 2017,March 31, 2018, compared to $25.7$7.5 million for 2016, an increase2017, a decrease in spendingcash of $122.9$1.9 million. The change was due to the acquisition of Novel Ingredients for $125.0 million, partially offset by $1.0 million cash received from the sale of an administrative building in 2017 and a $1.1$0.9 million decreaseincrease in capital spending.
Approximately 60%40% of the 20172018 capital spending was for strategic growth initiatives and the remaining 40%60% was for plant maintenance projects. Approximately half of theOur expectation for 2018 capital expenditures is approximately $45 million due to additional requirements to support strategic growth investments were focused on the deep well injection system project atmanufacturing initiatives, along with continuous improvement in our Geismar, LA facility which accounts for approximately 30% of the Company's total capital expenditures. The Company expects to come in favorable to budget and spend $15 million total on the project, of which $2.0 million occurred in 2016 and $7.7 million occurred in the first three quarters of 2017, with the majority of the remaining $5.3 million of projected spending to occur in the fourth quarter 2017.plants.
Net cash from financing activities for the ninethree months ended September 30, 2017March 31, 2018 was $81.2$25.4 million, compared to a use of $41.6$5.7 million in 2016,2017, an increase in cash of $122.7$31.1 million. This increase in cash was largely due to $125.0 million increased loan borrowings for seasonal working capital needs which were primarily funded with cash on hand in the Novel Ingredients acquisition.first quarter of 2017.
InnophosThe Company may from time to time seek to acquire or otherwise retire outstanding debt through privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will depend on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors applicable at the time. The amounts involved may be material.
During the ninethree months ended September 30, 2017,March 31, 2018, the Company spent $3.9$1.7 million related to restructuring activities initiated during the third quarter of 2015, and anticipates spending $2.2$0.3 million within the next twelve months.
On September 30, 2017,March 31, 2018, the Company had cash and cash equivalents outside the United States of $25.3$33.5 million, or 77%82% of the Company's balance. The foreign cash amounts are not restricted by law to be used in other countries. OurThe Company's current operating plan does not include any other repatriation of any additional cash and cash equivalents held outside the United States to fund the United States operations. However, in the event we do repatriate cash and cash equivalents held outside of the United States, we may be required to accrue and pay United Statesadditional taxes, such as withholding taxes, to repatriate these funds.
The Company’s available financial resources allow for the continuation of dividend payments, pursuit of acquisition
projects and further geographic expansion initiatives. We further believe that on hand cash combined with cash generated from
operations, including our Mexican operations, and availability under our revolving line of credit in our credit agreement, will be sufficient to meet our obligations such as debt service, tax payments, capital expenditures and working capital requirements for at least the next twelve months. We expect to fund all these obligations through our existing cash, our future operating cash flows and our existing revolving line of credit. However, future operating performance for the Company is subject to prevailing
economic and competitive conditions and various other factors that are uncertain. If the cash flows and other capital resources
available to the Company, such as its revolving loan facility, are insufficient to fund our debt and other liquidity needs, the
Company may have to take alternative actions that differ from current operating plans.
Critical Accounting Estimates and Policies
There have been no material changes from the critical accounting estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.2017.
| |
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in interest rates, as borrowings under our credit agreement will bear interest at floating rates based on LIBOR plus an applicable borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows. Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are held constant.
At September 30, 2017,March 31, 2018, we had a $450.0 million revolving credit facility, of which $295.0$345.0 million of variable-rate debt was outstanding, which approximates fair value (determined using level 2 inputs within the fair value hierarchy). Total remaining availability was $153.9$103.9 million, taking into account $1.1 million in face amount of letters of credit issued under the sub-facility. In December 2012, Innophos entered into an interest rate swap, swapping the LIBOR exposure on $100.0 million of floating rate debt, which is currently outstanding under our current credit agreement, with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cash flow hedge with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap of approximately $0.1 million (determined using level 2 inputs within the fair value hierarchy) is recorded in other long-term liabilities as of September 30, 2017.
Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds available for capital investment, operations or other purposes. In addition, a substantial portion of our operating cash flow and available borrowing capacity on our credit facility has been used to repurchase shares, pay dividends, fund capital expenditures, fund working capital needs and service debt, which may affect our ability to make future acquisitions. We have and may continue, from time to time usedbut presently do not, use interest rate protection agreements to minimize our exposure to interest rate fluctuation. Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest rate fluctuations. Based on $195.0$345.0 million outstanding borrowings as floating rate debt, (amount not covered by the swap), an immediate increase of one percentage point would cause an increase to interest expense of approximately $2.0$3.5 million per year.
We do not currently, but may from time to time, hedge our currency rate and energy risks.
We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales in the last 3 years.
Foreign Currency Exchange Rates
The US Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations’ monetary assets and liabilities are remeasured at current exchange rates, non-monetary assets and liabilities are remeasured at historical exchange rates, and revenue and expenses are remeasured at average exchange rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net income.
Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses, which are denominated in the foreign currency of the country in which we operate. A decline in the value of the US Dollar relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely, a decline in the value of the foreign currency relative to the US Dollar would cause these expenses to decrease). We believe that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses, and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in US Dollars and our exchange rate exposure in terms of sales revenues is minimal. However, the strength or weakness of the USDU.S. Dollar versus other currencies can affect our competitiveness in the USUnited States and export markets.
Inflation and changing prices
Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials, freight and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to customers, could have a material effect on our financial condition and results of operations.
Off-Balance Sheet Arrangements
We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as “structured finance or special purpose entities”, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
| |
ITEM 4. | CONTROLS AND PROCEDURES |
Disclosure Control and Procedures
The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934)1934, as amended) that are designed to provide reasonable assurance that information required to be reported in the Company's consolidated financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.
As of September 30, 2017,March 31, 2018, the Company completed an evaluation under the supervision and with the participation of the Company's management, including the Company's Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.
The Company acquired Novel Ingredients on August 25, 2017 and NutraGenesis on November 3, 2017, both wholly owned subsidiaries, and is in the process of evaluating and integrating these companies into the Company’s existing internal controls over financial reporting. The Management’s Report on Internal Control Over Financial Reporting to be included in the Annual Report on Form 10-K for the year ending December 31, 2018 will include Novel Ingredients and NutraGenesis, and the Company will disclose any material changes in its internal controls over financial reporting with respect to Novel Ingredients and NutraGenesis in future interim quarters and in the Annual Report on Form 10-K for the year ending December 31, 2018.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during or with respect to the thirdfirst quarter of 20172018 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. The Company acquired Novel Ingredients on August 25, 2017 and is in the process of evaluating and integrating this company into the Company’s existing internal control over financial reporting. The Management’s Report on Internal Control Over Financial Reporting to be included in the Annual Report on Form 10-K for the year ending December 31, 2017 will exclude Novel Ingredients, and we will disclose any material changes in our internal controls over financial reporting with respect to Novel Ingredients in the Annual Report on Form 10-K for the year ending December 31, 2018.
PART II - OTHER INFORMATION
Note 1415 of Notes to Consolidated Condensed Financial Statements in “Part I, Item 1. Financial Statements" contained in this Quarterly Report on Form 10-Q is incorporated herein by reference.
There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.2017.
| |
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
The Company did not have any share repurchases on the open market during the thirdfirst quarter of 2017.2018. From time to time, the Company reacquires shares from employees in connection with the vesting, exercise and forfeiture of awards under its equity compensation plans. No such re-aquisitions took place inIn the thirdfirst quarter of 2017.2018, the Company reacquired an aggregate of 6,188 shares at a price of $40.21 per share in connection with the surrender of restricted shares by employees for tax purposes.
| |
ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
None.
| |
ITEM 4. | MINE SAFETY DISCLOSURES |
None.
None.
a) Exhibits. The following exhibits are filed or furnished as part of this report:
|
| | |
Exhibit No. | | Description |
| | Certification of Principal Executive Officer dated October 31, 2017May 9, 2018 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | Certification of Principal Financial Officer dated October 31, 2017May 9, 2018 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | Certification of Principal Executive Officer dated October 31, 2017May 9, 2018 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | Certification of Principal Financial Officer dated October 31, 2017May 9, 2018 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | XBRL Instance Document |
| | XBRL Taxonomy Extension Schema Document |
| | XBRL Taxonomy Extension Calculation Linkbase Document |
| | XBRL Taxonomy Extension Definition Linkbase Document |
| | XBRL Taxonomy Extension Label Linkbase Document |
| | XBRL Taxonomy Extension Presentation Linkbase Document |
|
| |
* | Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933.1933, as amended. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
| |
INNOPHOS HOLDINGS, INC. |
| |
| /s/ Kim Ann Mink |
By: | Kim Ann Mink |
Its: | Chief Executive Officer, President and Director |
| (Principal Executive Officer) |
|
Dated: | October 31, 2017May 9, 2018 |
|
INNOPHOS HOLDINGS, INC. |
| |
| /s/ Han Kieftenbeld |
By: | Han Kieftenbeld |
Its: | Senior Vice President and Chief Financial Officer |
| (Principal Financial Officer) |
|
Dated: | October 31, 2017May 9, 2018 |
EXHIBIT INDEX
|
| | |
Exhibit No. | | Description |
31.1 | | Certification of Principal Executive Officer dated October 31, 2017May 9, 2018 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 | | Certification of Principal Financial Officer dated October 31, 2017May 9, 2018 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1* | | Certification of Principal Executive Officer dated October 31, 2017May 9, 2018 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2* | | Certification of Principal Financial Officer dated October 31, 2017May 9, 2018 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101.INS | | XBRL Instance Document |
101.SCH | | XBRL Taxonomy Extension Schema Document |
101.CAL | | XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | | XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | | XBRL Taxonomy Extension Presentation Linkbase Document |
|
| |
* | Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933.1933, as amended. |